

ARENA PHARMACEUTICALS INC
Form DEF 14A
April 24, 2008

[QuickLinks](#) -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

Arena Pharmaceuticals, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

o Fee paid previously with preliminary materials.

o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

ARENA PHARMACEUTICALS, INC.

April 24, 2008

Dear Arena Stockholder:

You are cordially invited to attend the 2008 Annual Meeting of Stockholders of Arena Pharmaceuticals, Inc., a Delaware corporation. The Annual Meeting will be held on Wednesday, June 11, 2008, at 9:00 a.m. Pacific Time, at our offices located at 6150 Nancy Ridge Drive, San Diego, California 92121. I look forward to meeting with as many of our stockholders as possible.

At the Annual Meeting, we will discuss each item of business described in the Notice of Annual Meeting and proxy statement and report on Arena's business. You will also have an opportunity to ask questions.

If you would like directions to our offices, please visit our website at www.arenapharm.com, where you will find directions and a map locator under "Contact Us." For further information about the Annual Meeting, please call 858.453.7200 and ask for Investor Relations.

On behalf of our employees and Board of Directors, I would like to express our appreciation for your continued interest in Arena.

Sincerely,

Jack Lief
*President, Chief Executive Officer and
Chairman of the Board*

6166 Nancy Ridge Drive, San Diego, California 92121

Notice of Annual Meeting of Stockholders
To be held on June 11, 2008

ARENA PHARMACEUTICALS, INC.

6166 Nancy Ridge Drive
San Diego, CA 92121

April 24, 2008

To the Stockholders of Arena Pharmaceuticals, Inc.:

The Annual Meeting of Stockholders of Arena Pharmaceuticals, Inc., a Delaware corporation, will be held on Wednesday, June 11, 2008, at 9:00 a.m. Pacific Time, at our offices located at 6150 Nancy Ridge Drive, San Diego, California 92121, for the following purposes, which are more fully described in the proxy statement accompanying this notice:

1. To elect 10 directors to our Board of Directors to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal;
2. To ratify the appointment of Ernst & Young LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2008; and
3. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.

Only stockholders of record at the close of business on April 14, 2008, are entitled to notice of and to vote at the Annual Meeting and at any adjournment or postponement thereof.

Whether or not you expect to attend in person, we urge you to sign, date and return the enclosed proxy card at your earliest convenience. This will ensure the presence of a quorum at the meeting. **Promptly signing, dating and returning the proxy card will save us the expense and extra work of additional solicitation.** You may return your proxy card in the enclosed envelope, which does not require postage if mailed in the United States. You may also vote by telephone or the Internet pursuant to the instructions that accompanied your proxy card. Sending in your proxy card or voting by telephone or the Internet will not prevent you from voting at the Annual Meeting if you desire to do so, as your proxy may be cancelled at your option. Please note, however, that if your shares are held of record by a bank, broker or other agent and you wish to vote at the meeting, you must obtain a proxy issued in your name from that record holder.

By Order of our Board of
Directors

Steven W. Spector
*Senior Vice President, General
Counsel and Secretary*

TABLE OF CONTENTS

Information Concerning Solicitation and Voting	1
General	1
Questions and Answers About these Proxy Materials and Voting	1
Election of Directors (<i>Proposal 1</i>)	5
Nominees and Election Process	5
Business Experience of Directors	5
Director Independence	7
Annual Performance Evaluations and Assessment of Charters	8
Code of Business Conduct and Ethics	8
Non-employee Director Meetings	8
Director Meeting Attendance	8
Board Standing Committees	9
Stockholder Director Recommendations	11
Stockholder Communications with our Board of Directors	12
Compensation Committee Interlocks and Insider Participation	12
Certain Relationships and Related Transactions	12
Compensation and Other Information Concerning Executive Officers, Directors and Certain Stockholders	13
Security Ownership of Certain Beneficial Owners and Management	13
Executive Officers	16
Compensation Discussion and Analysis	17
<i>Introduction</i>	17
<i>Executive Officer Compensation Philosophy, Objectives and Development</i>	17
<i>Elements of Our Compensation Program</i>	19
<i>Tax Considerations</i>	24
Compensation Committee Report	24
Summary Compensation Table for Fiscal Years Ended December 31, 2007 and 2006	25
Grants of Plan-Based Awards During Fiscal Year Ended December 31, 2007	27
Outstanding Equity Awards at Fiscal Year Ended December 31, 2007	29
Option Exercises and Stock Vested During Fiscal Year Ended December 31, 2007	30
Nonqualified Deferred Compensation Table for Fiscal Year Ended December 31, 2007	30
Potential Post-Employment Payments Table as of Fiscal Year Ended December 31, 2007	31
Director Compensation	33
<i>2007 Fiscal Year</i>	33
<i>Director Compensation Table for Fiscal Year Ended December 31, 2007</i>	35
<i>2008 Fiscal Year</i>	37
Audit Committee	38
Audit Committee Report	38
Independent Auditors' Fees	39
Pre-approval Policies and Procedures	39
Ratification of Independent Auditors (<i>Proposal 2</i>)	39
Section 16(a) Beneficial Ownership Reporting Compliance	40
Stockholder Proposals for the 2009 Annual Meeting	40
Annual Report	40
Annual Report on Form 10-K	40
Householding of Proxy Materials	41
Other Matters	41

ARENA PHARMACEUTICALS, INC.

6166 Nancy Ridge Drive
San Diego, CA 92121

PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS

To Be Held on Wednesday, June 11, 2008, at 9:00 a.m. Pacific Time

Information Concerning Solicitation and Voting

In this proxy statement, "Arena Pharmaceuticals," "Arena," "we," "us" and "our" refer to Arena Pharmaceuticals, Inc. and our wholly owned subsidiaries, unless the context otherwise provides.

General

The enclosed proxy is solicited on behalf of our Board of Directors for use at our 2008 Annual Meeting of Stockholders, which is to be held on Wednesday, June 11, 2008, at 9:00 a.m. Pacific Time, or at any adjournments or postponements thereof, for the purposes set forth in this proxy statement and the accompanying Notice of Annual Meeting of Stockholders. Our 2008 Annual Meeting will be held at our offices located at 6150 Nancy Ridge Drive, San Diego, California.

This proxy statement, together with the Notice of Annual Meeting of Stockholders, the form of proxy and our Annual Report to Stockholders, are first being mailed on or about April 24, 2008 to all stockholders of record at the close of business on the record date, which is April 14, 2008 (the "Record Date").

Questions and Answers About these Proxy Materials and Voting

Q:

Why am I receiving these materials?

A:

You are receiving these proxy materials in connection with our 2008 Annual Meeting of Stockholders, which is to be held on Wednesday, June 11, 2008, at 9:00 a.m. Pacific Time. As a stockholder, you are requested to vote on the proposals described in this proxy statement.

Q:

Who can vote at our 2008 Annual Meeting?

A:

Each person who owns or has the right to vote shares of our common stock or Series B Convertible Preferred Stock, which we refer to as our Preferred Stock, as of the Record Date has the right to vote at the meeting. Our common stock and our Preferred Stock will vote together on the proposals set forth in this proxy statement. Each share of our common stock is entitled to one vote, each share of our Series B-1 Preferred Stock is entitled to 1,582 votes (representing one vote for each share of common stock that the Series B-1 Preferred Stock is convertible into), and each share of our Series B-2 Preferred Stock is entitled to 1,607 votes (representing one vote for each share of common stock that the Series B-2 Preferred Stock is convertible into). As of the Record Date, there were 73,844,005 shares of our common stock, 3,500 shares of our Series B-1 Preferred Stock, and 1,150 shares of our Series B-2 Preferred Stock outstanding.

Stockholder of Record: Shares Registered in Your Name. If on the Record Date your shares of common stock were registered directly in your name with our transfer agent, Computershare Trust Company, N.A., then you are a stockholder of record. As a stockholder of record, you may vote in person at the meeting or vote by proxy.

Beneficial Owner: Shares Registered in the Name of a Bank, Broker or Other Agent. If on the Record Date your shares of common stock were held in an account by a bank, broker or other agent, then you are the beneficial owner of shares held in "street name" and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered the stockholder of record for purposes of voting at the meeting. As

a beneficial owner, you have the right to direct your bank, broker or other agent on how to vote the shares in your account. You are also invited to attend the meeting. However, since you are not the stockholder of record, you may not vote your shares in person at the meeting unless you request and obtain a legal proxy from your bank, broker or other agent.

Q:

What is the proxy card?

A:

The proxy card enables you to appoint Jack Lief, our President and Chief Executive Officer, and Steven W. Spector, our Senior Vice President, General Counsel and Secretary, as your representatives at our 2008 Annual Meeting. By completing and returning the proxy card, you are authorizing Mr. Lief and Mr. Spector, or each of them, to vote your shares at the meeting as described on the proxy card. This way, you can vote your shares whether or not you attend the meeting.

Q:

What am I voting on?

A:

We are asking you to vote on the following proposals:

1. The election of 10 directors to our Board of Directors to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal;
2. The ratification of the appointment of Ernst & Young LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2008; and
3. Such other proposals as may properly come before the meeting or any adjournment or postponement thereof.

Q:

How do I vote?

A:

Stockholder of Record: Shares Registered in Your Name

BY MAIL: Please complete and sign your proxy card and mail it in the enclosed pre-addressed envelope, which does not require postage if mailed in the United States. If you mark your voting instructions on the proxy card, your shares will be voted as you instruct, or in the best judgment of Mr. Lief or Mr. Spector if a proposal comes up for a vote at the meeting that is not on the proxy card.

If you do not mark your voting instructions on the proxy card, your shares will be voted as follows: FOR the 10 named nominees as directors, FOR the ratification of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2008, and according to the best judgment of Mr. Lief or Mr. Spector if a proposal that is not on the proxy card comes up for a vote at the meeting.

BY TELEPHONE: Please follow the vote by telephone instructions that are on your proxy card. If you vote by telephone, you do not have to mail in your proxy card.

BY INTERNET: Please follow the vote by Internet instructions that are on your proxy card. If you vote by Internet, you do not have to mail in your proxy card.

IN PERSON: We will pass out written ballots to anyone who wants to vote in person at the meeting. However, if you hold your shares in street name, you must request a legal proxy from your bank, broker or other agent in order to vote at the meeting.

A:

Beneficial Owner: Shares Registered in the Name of a Bank, Broker or Other Agent

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

If you are a beneficial owner of shares registered in the name of a bank, broker or other agent, you should have received a proxy card and voting instructions with these proxy

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

materials from that organization rather than from us. Simply follow the instructions you received from that organization to ensure that your vote is counted. Please contact that organization if you did not receive a proxy card or voting instructions.

To vote in person at the meeting, you must obtain a legal proxy from your bank, broker or other agent. Follow the instructions from your bank, broker or other agent included with these proxy materials, or contact such agent to request a proxy form.

Q:

What does it mean if I receive more than one proxy card?

A:

It likely means that you hold our shares in multiple accounts at the transfer agent or with brokers or other custodians of your shares. Please complete and return **all** proxy cards you receive to ensure that all of your shares are voted.

Q:

Can I change my vote after submitting my proxy?

A:

Stockholder of Record: Shares Registered in Your Name. If you are a stockholder of record, you can revoke your proxy and change your vote at any time before the polls close at the meeting by: (i) signing another proxy card with a later date and returning it before the polls close at the meeting, (ii) voting by telephone or the Internet before 11:00 p.m. Pacific Time on June 10, 2008 (your *latest* telephone or Internet vote is counted), (iii) returning a written notice before the polls close at the meeting that you are revoking your proxy, or (iv) voting at the meeting. Please note, however, that simply attending the meeting will not, by itself, revoke your proxy.

A:

Beneficial Owner: Shares Registered in the Name of a Bank, Broker or Other Agent. If you are a beneficial owner of shares registered in the name of a bank, broker or other agent, you should follow their instructions on how to change your vote. Please contact your bank, broker or other agent if you did not receive such instructions.

Q:

How many shares must be present to hold the meeting?

A:

To hold the meeting and conduct business, the holders of a majority of our outstanding common stock (determined as if our Preferred Stock was converted into common stock) as of the Record Date must be present, either in person or represented by proxy, at the meeting. This is called a quorum.

A stockholder's shares are counted towards a quorum if the stockholder either:

is present and votes in person at the meeting, or

has properly submitted a proxy (including voting by telephone or the Internet).

Both abstentions and broker non-votes are counted as present for the purposes of determining the presence of a quorum. Broker non-votes occur when a broker who holds shares for a stockholder in street name submits a proxy for those shares but does not vote. In general, this occurs when the broker has not received voting instructions from the stockholder, and the broker lacks discretionary voting power under the rules of the Financial Industry Regulatory Authority or otherwise to vote the shares.

Q:

How many votes must the nominees receive to be elected as directors?

A:

Directors are elected by a plurality of votes of common stock (determined as if our Preferred Stock was converted into common stock) present, either in person or represented by proxy, at the meeting and entitled to vote. This means that the 10 nominees receiving the highest number of votes FOR election will be elected.

Q: *How many votes must the ratification of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2008 receive to be approved?*

A: A majority of the shares of common stock (determined as if our Preferred Stock was converted into common stock) present, either in person or represented by proxy, at the meeting and entitled to vote must vote FOR ratification.

Q: *How may I vote and how are votes counted?*

A: You may vote either FOR any one or more of the director nominees or WITHHOLD your vote from any one or more of such nominees. You may vote FOR, AGAINST or ABSTAIN from voting on each of the other proposals. If you abstain from voting on any proposal that allows for abstention, it will have the same effect as a vote AGAINST such proposal. Broker non-votes will not affect the outcome of the voting on any of the other proposals described in this proxy statement.

Voting results are tabulated and certified by our transfer agent, Computershare Trust Company, N.A.

Q: *Who will bear the cost of soliciting votes for the meeting?*

A: We are paying for the distribution and solicitation of the proxies. As a part of this process, we reimburse brokers, nominees, fiduciaries and other custodians for reasonable fees and expenses in forwarding proxy materials to our stockholders. Original solicitation of proxies by mail may be supplemented by other mailings, telephone calls, personal solicitation, or use of the Internet by our directors, officers, other employees or, if we choose to engage one, an independent proxy solicitation firm. No additional compensation will be paid to our directors, officers or other employees for such services, and, in the event we engage such a proxy solicitation firm, the fees paid by us would not likely exceed \$20,000.

Q: *How can I obtain the company's corporate governance information?*

A: Our website is www.arenapharm.com and we have included various corporate governance materials under the "Investors" tab. Included in such information are the charters of Board of Directors' standing committees: the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee. Also included under that tab are our Code of Business Conduct and Ethics and our Policy on Filing, Receipt and Treatment of Complaints.

Election of Directors (Proposal 1)**Nominees and Election Process**

The persons named below are nominees for director to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal. Our Bylaws provide that the authorized number of directors shall be determined by a resolution of our Board of Directors.

Each nominee listed below other than Messrs. Schneider and Woods was elected at our 2007 annual meeting of stockholders. Mr. Schneider was identified by one of our non-employee directors, and Mr. Woods was identified by a third-party search firm. We retained the third-party search firm at the direction of the Corporate Governance and Nominating Committee, and the search firm assisted such committee in identifying and evaluating potential nominees. All of the nominees were recommended for election to our Board of Directors by the Corporate Governance and Nominating Committee. Directors are elected by a plurality of votes present in person or represented by proxy at the annual meeting of stockholders and entitled to vote. Unless otherwise instructed to withhold a vote for a particular nominee or all of the nominees, the proxy holders will vote the proxies received by them for the nominees named below. In the event that any of these nominees is unavailable to serve as a director at the time of our 2008 Annual Meeting, the proxies will be voted for any substitute nominee who shall be designated by our Board of Directors, unless our Board reduces the number of directors. We have no reason to believe that any nominee will be unavailable to serve.

The following table sets forth information regarding the nominees as of March 31, 2008.

Name	Positions and Offices Held	Year First Elected or Appointed Director	Age
Jack Lief	President, Chief Executive Officer and Chairman of the Board	1997	62
Dominic P. Behan, Ph.D.	Senior Vice President, Chief Scientific Officer and Director	2000	44
Donald D. Belcher	Director	2003	69
Scott H. Bice	Director	2003	65
Harry F. Hixson, Jr., Ph.D.	Director	2004	69
J. Clayburn La Force, Jr., Ph.D.	Director	2002	79
Tina Nova Bennett, Ph.D.	Director	2004	54
Phillip M. Schneider	Director	2007	51
Christine A. White, M.D.	Director	2006	56
Randall E. Woods	Director	2007	56

Business Experience of Directors

Jack Lief is a co-founder of Arena and has served as a director and our President and Chief Executive Officer since April 1997. Mr. Lief has also served as the Chairman of our Board of Directors since October 2007. From 1995 to April 1997, Mr. Lief served as an advisor and consultant to numerous biopharmaceutical organizations. From 1989 to 1994, Mr. Lief served as Senior Vice President, Corporate Development and Secretary of Cephalon, Inc., a biopharmaceutical company. From 1983 to 1989, Mr. Lief served as Director of Business Development and Strategic Planning for Alpha Therapeutic Corporation, a manufacturer of biological products. Mr. Lief joined Abbott Laboratories, a pharmaceutical company, in 1972, where he served until 1983, most recently as the head of International Marketing Research. Mr. Lief serves as a member of the board of directors of Adventrx Pharmaceuticals, Inc., a research and development company focused on pharmaceuticals for cancer and infectious disease. Mr. Lief is also an Executive Board Member of BIOCOM, a life science industry association representing more than 550 member companies in Southern California, and was

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

the Chairman of the board of directors of BIOCUM from March 2005 to March 2006. Mr. Lief holds a B.A. from Rutgers University and an M.S. in Psychology (Experimental and Neurobiology) from Lehigh University.

Dominic P. Behan, Ph.D., is a co-founder of Arena and has served as a director since April 2000, and as our Senior Vice President and Chief Scientific Officer since June 2004. Dr. Behan served as our Vice President, Research from April 1997 to June 2004. From 1993 to January 1997, Dr. Behan directed various research programs at Neurocrine Biosciences, Inc., a biopharmaceutical company. From 1990 to 1993, Dr. Behan was engaged in research at the Salk Institute. Dr. Behan holds a B.Sc. in Biochemistry from Leeds University, England, and a Ph.D. in Biochemistry from Reading University, England.

Donald D. Belcher has served as a member of our Board of Directors since December 2003. Mr. Belcher served as Chairman of the board of directors of Banta Corporation, a printing and supply-chain management company, from May 1995 to April 2004, Chief Executive Officer from January 1995 to October 2002 and President from September 1994 to January 2001. Mr. Belcher holds a B.A. from Dartmouth College and an M.B.A. from the Stanford University Graduate School of Business.

Scott H. Bice has served as a member of our Board of Directors since December 2003. Since June 2000, Mr. Bice has been the Robert C. Packard Professor at the University of Southern California Law School, where he served as Dean from 1980 to June 2000. Mr. Bice has experience on several corporate boards, including Imagine Films, from 1992 to 1994, Western and Residence Mutual Insurance Companies, from 1996 to 2003, and Jenny Craig, from 1996 to 2002. Mr. Bice holds a B.S. in finance and a J.D. from the University of Southern California.

Harry F. Hixson, Jr., Ph.D., has served as a member of our Board of Directors since September 2004. Dr. Hixson has served as Chairman of the board of directors of BrainCells Inc., a neurogenesis-based drug discovery and development company, since December 2003. Dr. Hixson served as Chief Executive Officer of BrainCells Inc. from July 2004 to September 2005 and as Chief Executive Officer of Elitra Pharmaceuticals, a biopharmaceutical company, from February 1998 to May 2003. Dr. Hixson held various management positions with Amgen, Inc., a biopharmaceutical company, from 1985 to 1991, most recently as President and Chief Operating Officer. Dr. Hixson serves as a member of the board of directors of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company, and as the Chairman of the board of directors of Sequenom, Inc., a genomics company. Dr. Hixson holds a B.S. in Chemical Engineering from Purdue University, an M.B.A. from the University of Chicago and a Ph.D. in Physical Biochemistry from Purdue University.

J. Clayburn La Force, Jr., Ph.D., has served as a member of our Board of Directors since October 2002. Dr. La Force served as a professor of Economics at the University of California, Los Angeles from 1962 to 1978, and served as Dean of the Anderson School of Management at the University of California, Los Angeles from July 1978 to June 1993. From 1969 to 1978, Dr. La Force served as the Chairman of the Economics Department at the University of California, Los Angeles. Dr. La Force currently serves as a member of the board of directors of the following registered investment companies: Payden Funds, Metzler Payden, and Advisors Series Trust. Dr. La Force holds an A.B. in Economics from San Diego State College and an M.A. and a Ph.D. in Economics from the University of California, Los Angeles.

Tina Nova Bennett, Ph.D., has served as a member of our Board of Directors since September 2004. Dr. Nova Bennett is a co-founder of Genoptix, Inc., a provider of personalized medicine services, and has served as its President and Chief Executive Officer and as a member of its board of directors since March 2000. Dr. Nova Bennett was a co-founder of Nanogen, Inc., a provider of molecular diagnostic tests, where she served as Chief Operating Officer and President from 1994 to January 2000. From 1992 to 1994, Dr. Nova Bennett served as Chief Operating Officer of Selective Genetics, a targeted therapy, biotechnology company. From 1988 to 1992, Dr. Nova Bennett held various director-

level positions with Ligand Pharmaceuticals Incorporated, a drug discovery and development company, most recently serving as Executive Director of New Leads Discovery. Dr. Nova Bennett has also held various research and management positions with Hybritech, Inc., a former subsidiary of Eli Lilly & Company, a pharmaceutical company. Dr. Nova Bennett serves as a member of the Board of Directors of Cypress Biosciences, Inc., a company focused on developing drugs for functional somatic syndromes. Dr. Nova Bennett is the life science sector representative to the Independent Citizen's Oversight Committee overseeing the implementation of the California stem cell initiative, Proposition 71. Dr. Nova Bennett holds a B.S. in Biological Sciences from the University of California, Irvine and a Ph.D. in Biochemistry from the University of California, Riverside.

Phillip M. Schneider has served as a member of our Board of Directors since December 2007. From 1987 to 2002, Mr. Schneider held various positions with IDEC Pharmaceuticals Corporation, a biopharmaceutical company, most recently as Senior Vice President and Chief Financial Officer. Prior to his association with IDEC, Mr. Schneider held various management positions at Syntex Pharmaceuticals Corporation and was previously with KPMG, LLP. Mr. Schneider is a member of the board of directors of Gen-Probe, Inc., a medical diagnostics company. Mr. Schneider holds an M.B.A. from the University of Southern California and a B.S. in Biochemistry from the University of California, Davis.

Christine A. White, M.D., has served as a member of our Board of Directors since August 2006. Dr. White was with Biogen Idec Inc., a biopharmaceutical company, from 1996 to 2005, where she held several senior positions, most recently as Senior Vice President, Global Medical Affairs. From 1994 to 1996, Dr. White served as the Director of Clinical Oncology Research at the Sidney Kimmel Cancer Center in San Diego and from 1984 to 1994, Dr. White was on the clinical staff and held various positions in the Department of Medicine at Scripps Memorial Hospitals in La Jolla and Encinitas, California, most recently as Chairman, Department of Medicine. Dr. White serves as a member of the board of directors at Pharmacyclics, Inc, a pharmaceutical company developing products to treat cancer and other diseases. Dr. White holds a B.A. in Biology and an M.D. from the University of Chicago and is Board certified in both Internal Medicine and Medical Oncology.

Randall E. Woods has served as a member of our Board of Directors since December 2007. Mr. Woods is the President and Chief Executive Officer and a member of the board of directors of Sequel Pharmaceuticals, Inc., a pharmaceutical company. From April 2004 to September 2007, Mr. Woods was the President and Chief Executive Officer of NovaCardia, Inc., a pharmaceutical company, prior to its acquisition by Merck & Co. Previously, Mr. Woods served approximately eight years as the Chief Executive Officer of Corvas International, Inc., a biopharmaceutical company. He was also President of Boehringer Mannheim's U.S. pharmaceutical operations and spent more than 20 years at Eli Lilly & Company in sales and marketing positions. Mr. Woods serves as the chairman of the advisory board of the University of California, San Diego's Sulpizio Family Cardiovascular Center, and is an Executive Board Member, and the incoming chair of the board of directors, of BIOCOM. Mr. Woods holds an M.B.A. from Western Michigan University and a B.S. in Biology and Chemistry from Ball State University.

THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE "FOR" EACH NAMED NOMINEE.

Director Independence

Our common stock is listed on the NASDAQ Global Market, which requires that a majority of a listed company's board of directors qualify as "independent" under the applicable NASDAQ listing standards. The board of directors must affirmatively make this determination.

Our Board of Directors consults with our General Counsel to ensure that our Board's independence determinations comply with all applicable securities and other laws and regulations

regarding the definition of "independent," including but not limited to those set forth in pertinent listing standards of NASDAQ, as in effect from time to time. Consistent with these considerations, our Board of Directors has reviewed relevant transactions and relationships between each non-employee director and Arena, our senior management and our independent auditors and has affirmatively determined that all of our non-employee directors are independent directors under the applicable NASDAQ listing standards. Our Board of Directors also determined that Louis J. Lavigne, Jr., who served as one of our directors from January 2005 to February 2007, was an independent director.

Annual Performance Evaluations and Assessment of Charters

Our Board of Directors, as well as each of its standing committees, conducts an annual self-evaluation, which includes a review of its performance and, in the case of each of the committees, an assessment of the adequacy and appropriateness of its charter. The Corporate Governance and Nominating Committee is responsible for overseeing this evaluation process, evaluating all standing committees and their charters and recommending to our Board of Directors any changes to the authority, charters, compositions and chairs of such committees.

Code of Business Conduct and Ethics

Our Board of Directors has adopted a Code of Business Conduct and Ethics that applies to our directors and employees (including our principal executive officer, principal financial officer, principal accounting officer and controller), and we have posted the text of the policy on our website (www.arenapharm.com) under the "Corporate Governance" section. To facilitate compliance with this policy, we periodically conduct a program of awareness, training and review. The Code of Business Conduct and Ethics complies with the applicable NASDAQ listing standards and the Securities and Exchange Commission, or SEC, rules and regulations and includes procedures for (i) the filing, receipt and treatment of complaints regarding suspected improper conduct by our employees, directors, collaborators, vendors and others associated with us and (ii) the confidential, anonymous submission by employees of concerns regarding any matter covered by the policy. In addition, we intend to promptly disclose (i) the nature of any amendment to the policy that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions and (ii) the nature of any waiver, including an implicit waiver, from a provision of the policy that is granted to one of these specified individuals, the name of such person who is granted the waiver and the date of the waiver on our website and, as applicable, in filings on Form 8-K in the future.

Non-employee Director Meetings

Our independent directors meet in regularly scheduled executive sessions at which only independent directors are present. These executive sessions occur in conjunction with regularly scheduled meetings of our Board of Directors and its standing committees and otherwise as needed.

Director Meeting Attendance

Our Board of Directors held eight meetings during the fiscal year ended December 31, 2007. Each incumbent director attended at least 75% of the aggregate of the total number of meetings of our Board of Directors and the total number of meetings held by all committees of our Board on which such director served, in each case during the periods in which he or she served. In addition to regularly scheduled meetings, the directors participate in a considerable number of telephone interactions, including regular telephone calls among the independent directors and Mr. Lief, and other communications with each other and our executive officers, as well as with our independent auditors and external advisors, such as legal counsel, consultants and investment bankers.

It is our policy to encourage directors to attend our annual meetings of stockholders. Seven of eight of our then directors attended our 2007 annual meeting of stockholders.

Board Standing Committees

The standing committees of our Board of Directors are the Audit Committee, the Compensation Committee and the Corporate Governance and Nominating Committee. All of the standing committees of our Board of Directors are comprised entirely of independent directors. The chairs of the standing committees are appointed by our Board of Directors and may change in the future. Pursuant to their charters, each of the committees is authorized to access, at our expense, such internal and external resources as the particular committee deems necessary or appropriate to fulfill its defined responsibilities. Each committee has sole authority to approve fees, costs and other terms of engagement of such outside resources.

Below is a chart showing the structure and membership of the standing committees of our Board of Directors as of March 31, 2008.

Member	Audit Committee	Compensation Committee	Corporate Governance and Nominating Committee
Donald D. Belcher			
Scott H. Bice			
Harry F. Hixson, Jr., Ph.D.			
J. Clayburn La Force, Jr., Ph.D.			
Tina Nova Bennett, Ph.D.			
Phillip M. Schneider			
Christine A. White, M.D.			
Randall E. Woods			

- = Committee member
- = Committee chair

Immediately following the filing of this proxy statement with the SEC, we expect the structure and membership of the standing committees of our Board of Directors to change as set forth below.

Member	Audit Committee	Compensation Committee	Corporate Governance and Nominating Committee
Donald D. Belcher			
Scott H. Bice			
Harry F. Hixson, Jr., Ph.D.			
J. Clayburn La Force, Jr., Ph.D.			
Tina Nova Bennett, Ph.D.			

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

Member	Audit Committee	Compensation Committee	Corporate Governance and Nominating Committee
Phillip M. Schneider			
Christine A. White, M.D.			
Randall E. Woods			

Audit Committee

The Audit Committee's responsibilities include:

- (i) selecting and evaluating the performance of our independent auditors;
- (ii) reviewing the scope of the audit to be conducted by our independent auditors, as well as the results of their audit, and approving audit and non-audit services to be provided by them;
- (iii) reviewing and assessing our financial reporting activities, including our periodic reports, and the accounting standards and principles followed;
- (iv) reviewing the organization and scope of our internal system of financial controls and reporting;
- (v) reviewing and assessing our guidelines and policies with respect to risk assessment and management, our tax strategy and our investment policy;
- (vi) reviewing and approving related-party transactions; and
- (vii) overseeing our Code of Business Conduct and Ethics and our Policy on Filing, Receipt and Treatment of Complaints.

Our Board of Directors has determined that each of the Audit Committee members meets the independence and experience requirements included in the applicable NASDAQ listing standards and Rule 10A-3(b)(1) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our Board of Directors has also determined that Mr. Belcher, the Chair of the Audit Committee, is an "audit committee financial expert" as defined in Item 407(d) of Regulation S-K.

Our Board of Directors has adopted a written charter for the Audit Committee, which is available on our website at www.arenapharm.com. The Audit Committee held nine meetings in 2007. The Audit Committee's report is set forth below under "Audit Committee Report."

Compensation Committee

The Compensation Committee's responsibilities include:

- (i) reviewing and approving corporate and individual performance goals relevant to the compensation of our executive officers;
- (ii) evaluating and recommending to our Board of Directors compensation plans and programs for Arena, as well as modifying or terminating existing plans and programs;
- (iii) reviewing and approving compensation and benefits for our directors and executive officers, and making recommendations to our Board of Directors regarding these matters;
- (iv) authorizing and approving equity grants under our equity compensation plans; and
- (v) overseeing preparation and review of the committee's report and the compensation discussion and analysis included in our proxy statement.

The primary purpose of the Compensation Committee is to act on behalf of our Board of Directors in fulfilling our Board's responsibilities to oversee our compensation policies, plans and programs. Specific functions of the Compensation Committee under its charter are to review,

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

modify and approve our overall compensation strategy and policies, review and determine the compensation of our executive officers and non-employee directors, administer our equity compensation plans (including reviewing and approving equity grants to our executive officers and directors), and to approve the adoption, amendment and termination of our benefit plans.

Our Board of Directors has adopted a written charter for the Compensation Committee, which is available on our website at www.arenapharm.com. Dr. La Force is the Chair of the Compensation Committee. Mr. Belcher served as the Chair of the Compensation Committee in 2007 until

Dr. La Force became the Chair of such committee in February of 2007. The Compensation Committee held seven meetings in 2007. The Compensation Committee's report is set forth below under "Compensation Committee Report."

Corporate Governance and Nominating Committee

The Corporate Governance and Nominating Committee's responsibilities include:

- (i) recommending guidelines to our Board of Directors for our corporate governance, including the structure and function of our Board and its committees and our management;
- (ii) reviewing and approving a management succession plan and related procedures;
- (iii) making recommendations regarding the agenda for our Board of Director's strategy discussions;
- (iv) overseeing compliance related policies and practices that are referred by our Board of Directors;
- (v) establishing criteria for membership on our Board of Directors;
- (vi) identifying, evaluating, reviewing and recommending to our Board of Directors qualified candidates to serve on our Board;
- (vii) making recommendations to our Board of Directors regarding the election of officers;
- (viii) serving as a focal point for communications between director candidates, non-committee directors and management; and
- (ix) reviewing and assessing the performance of our Board of Directors and each of its committees.

The Corporate Governance and Nominating Committee uses many sources to identify potential director candidates, including the network of contacts among our directors, officers and other employees, and may engage outside consultants and recruiters in this process. As set forth below under "Stockholder Director Recommendations," the Corporate Governance and Nominating Committee will consider director candidates recommended by our stockholders. The Corporate Governance and Nominating Committee believes that candidates for director should have certain minimum qualifications, including being able to understand basic financial statements. In considering candidates for director, the Corporate Governance and Nominating Committee will consider all relevant factors, which may include among others the candidate's experience and accomplishments, the relevance of such experience to our business, the availability of the candidate to devote sufficient time and attention to Arena, the candidate's reputation for integrity and ethics and the candidate's ability to exercise sound business judgment. The Corporate Governance and Nominating Committee retains the right to modify these qualifications from time to time, and candidates for director are reviewed in the context of the composition of the then current Board of Directors, our requirements and the interests of our stockholders. The Corporate Governance and Nominating Committee recommended the nominations of each of the directors nominated for election at our 2008 Annual Meeting.

Our Board of Directors has adopted a written charter for the Corporate Governance and Nominating Committee, which is available on our website at www.arenapharm.com. Mr. Bice is the Chair of the Corporate Governance and Nominating Committee. The Corporate Governance and Nominating Committee held five meetings in 2007.

Stockholder Director Recommendations

The Corporate Governance and Nominating Committee will consider director candidates recommended by our stockholders. A candidate must be highly qualified and be willing and expressly interested in serving on our Board of Directors. To be considered by the Corporate Governance and

Nominating Committee, a stockholder recommendation for director candidates for an annual meeting of stockholders must be received by the committee by December 31 of the year before such annual meeting. A stockholder who wishes to recommend a candidate for the Corporate Governance and Nominating Committee's consideration should forward the candidate's name and information about the candidate's qualifications to Corporate Secretary, Arena Pharmaceuticals, Inc., 6166 Nancy Ridge Drive, San Diego, California 92121. **Submissions must include a representation that the nominating stockholder is a beneficial or record owner of our stock. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected.** This procedure does not affect the deadline for submitting other stockholder proposals for inclusion in the proxy statement, nor does it apply to questions a stockholder may wish to ask at an annual meeting. Additional information regarding submitting stockholder proposals is set forth in our Bylaws. Stockholders may request a copy of the bylaw provisions relating to stockholder proposals from our Corporate Secretary.

Stockholder Communications with our Board of Directors

Our Board of Directors has a formal process by which stockholders may communicate with our Board or any of our directors or officers. Stockholders who wish to communicate with our Board of Directors or any of our directors or officers may do so by sending written communications addressed to such person or persons in care of Corporate Secretary, Arena Pharmaceuticals, Inc., 6166 Nancy Ridge Drive, San Diego, California 92121. All such communications to our directors will be compiled by our Corporate Secretary and submitted to the addressees on a periodic basis. If our Board of Directors modifies this process, we will post the revised process on our website.

Compensation Committee Interlocks and Insider Participation

Mr. Belcher and Drs. Hixson, La Force, Nova Bennett and White served on the Compensation Committee for at least part of 2007, and the committee currently consists of Drs. Hixson, La Force and White. No director serving on the Compensation Committee during any part of 2007 was, at any time during or before such fiscal year, one of our employees. None of our executive officers served during any part of 2007 as a member of the board of directors or compensation committee of any other entity that had one or more of its executive officers serving as members of our Board of Directors or its Compensation Committee.

Certain Relationships and Related Transactions

Except for the relationships between us and our executive officers and directors described below under "Compensation Discussion and Analysis," since January 1, 2007 we have not been a party to any transactions involving more than \$120,000 and in which any director, nominee for director, executive officer, holder of more than 5% of our common stock or any immediate family member of the foregoing has a direct or indirect material interest.

The Audit Committee's charter requires that it reviews and approves any related-person transactions. In considering related-person transactions, the Audit Committee considers the relevant available facts and circumstances, including, but not limited to, (i) the risks, costs and benefits to us, (ii) the impact on a director's independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated, (iii) the terms of the transaction, (iv) the availability of other sources for comparable services or products and (v) the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval. In determining whether to approve, ratify or reject a related-person transaction, the Audit Committee evaluates whether, in light of known circumstances, the transaction is in, or is not inconsistent with, our best interests and those of our stockholders.

Compensation and Other Information
Concerning Executive Officers, Directors and Certain Stockholders

Security Ownership of Certain Beneficial Owners and Management

The following table sets forth certain information known to us with respect to the beneficial ownership of our common stock as of March 21, 2008 by:

Each person, group or entity who is the beneficial owner of 5% or more of our common stock;

Each director and nominee for director;

Our Named Executive Officers; and

All current directors and executive officers as a group.

Unless otherwise indicated in the footnotes below, the address for the beneficial owners listed in this table is in care of Corporate Secretary, Arena Pharmaceuticals, Inc., 6166 Nancy Ridge Drive, San Diego, California 92121. This table is based on information supplied by executive officers, directors and principal stockholders and Schedules 13D, 13G and other filings made with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, we believe that the stockholders named in this table have sole voting and investment power with respect to the shares indicated as beneficially owned. Applicable percentages are based on 73,759,776 shares of common stock outstanding on March 21, 2008, including 31,000 restricted shares of common stock, and as adjusted as required by the rules promulgated by the SEC. This table includes shares issuable pursuant to stock options and other rights to purchase shares of our common stock exercisable within 60 days of March 21, 2008.

Name and Address of Beneficial Owner	Shares Beneficially Owned	Percentage of Total
Wellington Management Company, LLP(1)	9,758,683	13.2%
The Bank of New York Mellon Corporation(2)	7,517,844	10.2%
Entities affiliated with Deerfield Capital, L.P.(3)	5,950,643	8.1%
Mainfield Enterprises, Inc.(4)(5)	5,284,202	6.8%
Federated Investors, Inc.(6)	4,137,500	5.6%
TCW Business Unit(7)	3,907,696	5.3%
Smithfield Fiduciary LLC(5)(8)	3,963,647	5.2%
Jack Lief(9)	1,143,285	1.5%
Dominic P. Behan, Ph.D.(10)	681,948	*
Steven W. Spector, J.D.(11)	241,500	*
Robert E. Hoffman, C.P.A.(12)	190,294	*
J. Clayburn La Force, Jr., Ph.D.(13)	152,502	*
William R. Shanahan, Jr., M.D., J.D.(14)	141,250	*
Harry F. Hixson, Jr., Ph.D.(15)	104,916	*
Donald D. Belcher(16)	99,906	*
Scott H. Bice(17)	61,568	*
Tina Nova Bennett, Ph.D.(18)	59,000	*
Christine A. White, M.D.(19)	32,374	*
Phillip M. Schneider(20)	1,596	*
Randall E. Woods(21)	1,596	*
All directors and executive officers as a group (13 persons)(22)	3,096,299	4.1%

*
Less than one percent

(1)

The principal business office of Wellington Management Company, LLP is 75 State Street, Boston, Massachusetts 02109.

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

- (2) The principal business office of The Bank of New York Mellon Corporation is One Wall Street, 31st Floor, New York, New York 10286.
- (3) Represents shares held by Deerfield Capital, L.P., Deerfield Partners, L.P., Deerfield International Limited, Deerfield Management Company, L.P., and James E. Flynn. The principal business address of Deerfield Capital, L.P., Deerfield Partners, L.P., Deerfield Management Company, L.P., and James E. Flynn is 780 Third Avenue, 37th Floor, New York, New York 10017. The principal business address of Deerfield International Limited is c/o Bisys Management, Bison Court, Columbus Centre, P.O. Box 3460, Road Town, Tortola, British Virgin Islands.
- (4) Pursuant to an investment management agreement, Avi Vigder has voting discretion and investment control over the shares held by Mainfield Enterprises, Inc. Avi Vigder disclaims beneficial ownership of such shares. The principal business office of Mainfield Enterprises, Inc. is in care of Sage Capital Growth, Inc., 660 Madison Avenue, New York, New York 10022.
- (5) The holder disclaims beneficial ownership of our common stock that exceeds 4.999% of our outstanding common stock. Under the terms of our Preferred Stock, the number of shares of our common stock that may be acquired by the holder upon any conversion of our Preferred Stock is limited to the extent necessary to ensure that, following such conversion, the total number of shares of our common stock then beneficially owned by such holder and its affiliates and any other persons whose beneficial ownership of our common stock would be aggregated with the holders for purposes of Section 13(d) of the Securities Exchange of 1934 does not exceed 4.999% of our common stock (including shares of our common stock issuable upon such conversion). The holder can waive this provision or increase (but not to more than 9.999%) or decrease this percentage by giving us written notice, but (i) any such waiver or increase will not be effective until the 61st day after such notice is delivered to the us, and (ii) any such waiver or increase or decrease will apply only to such holder. The 4.999% limitation is disregarded for purposes of this table. This table includes the shares of our common stock that the holder may acquire by exercising warrants that they hold. The warrants provide that the number of shares of our common stock that may be acquired by the holder upon any exercise of the warrant is limited to the extent necessary to ensure that, following such exercise, the total number of shares of our common stock then beneficially owned by such holder and its affiliates and any other persons whose beneficial ownership of our common stock would be aggregated with the holders for purposes of Section 13(d) of the Securities Exchange of 1934 does not exceed 4.999% of our common stock (including shares of our common stock issuable upon such exercise). The holder can waive this limitation on exercise or increase or decrease the 4.999% by giving us written notice, but (i) any such waiver or increase will not be effective until the 61st day after such notice is delivered to us and (ii) any such waiver or increase or decrease will apply only to such holder and not to any other holder of warrants. This does not include any common shares of which the holder may have beneficial ownership.
- (6) The principal business office of Federated Investors, Inc. is Federated Investors Tower, 1001 Liberty Avenue, Pittsburgh, Pennsylvania 15222.
- (7) The principal business office of TCW Business Unit is The TCW Group, Inc, on behalf of the TCW Business Unit, 865 South Figueroa Street, Los Angeles, California 90017.
- (8) Highbridge Capital Management, LLC, is the trading manager of Smithfield Fiduciary LLC and consequently has voting control and investment discretion over securities held by Smithfield Fiduciary LLC. Glenn Dubin and Henry Swieca control Highbridge Capital Management, LLC. Each of Highbridge Capital Management, LLC, Glenn Dubin and Henry Swieca disclaims beneficial ownership of the securities held by Smithfield Fiduciary LLC. The principal business office of Smithfield Fiduciary LLC is in care of Highbridge Capital Management, LLC, 9 West 57th Street, 27th Floor, New York, New York 10019.

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

- (9) Includes 603,600 shares issuable to Mr. Lief upon the exercise of stock options that are exercisable within 60 days of March 21, 2008. Also includes 12,000 restricted shares of our common stock which are scheduled to vest on January 20, 2009.
- (10) Includes 346,448 shares issuable to Dr. Behan upon the exercise of stock options that are exercisable within 60 days of March 21, 2008. Also includes 5,000 restricted shares of our common stock which are scheduled to vest on January 20, 2009.
- (11) Includes 187,500 shares issuable to Mr. Spector upon the exercise of stock options that are exercisable within 60 days of March 21, 2008. Also includes 5,000 restricted shares of our common stock which are scheduled to vest on January 20, 2009.
- (12) Includes 123,750 shares issuable to Mr. Hoffman upon the exercise of stock options that are exercisable within 60 days of March 21, 2008. Also includes 5,000 restricted shares of our common stock which are scheduled to vest on January 20, 2009.
- (13) Includes 152,502 shares issuable to Dr. La Force upon the exercise of stock options that are exercisable within 60 days of March 21, 2008.
- (14) Includes 141,250 shares issuable to Dr. Shanahan upon the exercise of stock options that are exercisable within 60 days of March 21, 2008.
- (15) Includes 94,916 shares issuable to Dr. Hixson upon the exercise of stock options that are exercisable within 60 days of March 21, 2008.
- (16) Includes 94,906 shares issuable to Mr. Belcher upon the exercise of stock options that are exercisable within 60 days of March 21, 2008.
- (17) Includes 60,468 shares issuable to Mr. Bice upon the exercise of stock options that are exercisable within 60 days of March 21, 2008.
- (18) Includes 59,000 shares issuable to Dr. Nova Bennett upon the exercise of stock options that are exercisable within 60 days of March 21, 2008.
- (19) Includes 32,374 shares issuable to Dr. White upon the exercise of stock options that are exercisable within 60 days of March 21, 2008.
- (20) Includes 1,596 shares issuable to Mr. Schneider upon the exercise of stock options that are exercisable within 60 days of March 21, 2008.
- (21) Includes 1,596 shares issuable to Mr. Woods upon the exercise of stock options that are exercisable within 60 days of March 21, 2008.
- (22) Includes 2,053,656 shares issuable upon the exercise of stock options held by our directors and executive officers that are exercisable within 60 days of March 21, 2008. Also includes 27,000 restricted shares of our common stock that we granted our executive officers.

Executive Officers

Our executive officers are appointed by our Board of Directors and serve at the discretion of our Board. Set forth below are the names and certain biographical information regarding our executive officers as of March 31, 2008.

Name	Age	Position
Jack Lief	62	President, Chief Executive Officer and Chairman of the Board
K.A. Ajit-Simh	55	Vice President, Quality Systems
Dominic P. Behan, Ph.D.	44	Senior Vice President and Chief Scientific Officer
Robert E. Hoffman, C.P.A.	42	Vice President, Finance and Chief Financial Officer
Louis J. Scotti	52	Vice President, Marketing and Business Development
William R. Shanahan, Jr., M.D., J.D.	59	Vice President and Chief Medical Officer
Steven W. Spector, J.D.	43	Senior Vice President, General Counsel and Secretary

See "Election of Directors (*Proposal 1*)" for biographical information regarding Mr. Lief and Dr. Behan, who are also directors.

K.A. Ajit-Simh has served as our Vice President, Quality Systems since January 2004. Mr. Ajit-Simh provided regulatory compliance services to several companies in the United States and internationally from 1999 to the end of 2003. Mr. Ajit-Simh held various positions of increasing responsibility at Mallinckrodt Inc. from 1975 to 1985, Baxter Healthcare from 1986 to 1989, Abbott BioTech from 1989 to 1992, and Cytel Corporation from 1992 to 1999. In addition, he has been an instructor at the University of California, San Diego since 1994, teaching classes in regulatory compliance and quality control/assurance. He also teaches courses in Good Manufacturing Practices and Advanced Quality Control and Assurance at San Diego State University as part of the graduate program in Regulatory Affairs. Mr. Ajit-Simh received a B.Sc. degree in Biology and Chemistry from Bangalore University and an M.S. in Cell Biology from St. Louis University.

Robert E. Hoffman, C.P.A., has served as our Vice President, Finance and Chief Financial Officer since December 2005. Mr. Hoffman served as our Vice President, Finance and Chief Accounting Officer from June 2004 to December 2005, as our Vice President, Finance from April 2000 to June 2004, and as our Controller from August 1997 to April 2000. From 1994 to 1997, Mr. Hoffman served as Assistant Controller for Document Sciences Corporation, a software company. Mr. Hoffman serves as a member of the steering committee of the Association of Bioscience Financial Officers and as a supervisory committee member of the San Diego County Credit Union. He is also a director and the immediate-past President of the San Diego chapter of Financial Executives International. Mr. Hoffman holds a B.B.A. from St. Bonaventure University and is licensed as a C.P.A. in the State of California.

Louis J. Scotti has served as our Vice President, Marketing and Business Development since September 2002. He previously served as our Vice President, Business Development from August 1999 to September 2002. From June 1998 to July 1999, Mr. Scotti served as President and Chief Executive Officer for ProtoMed, Inc., a biopharmaceutical company. From April 1996 to June 1998, Mr. Scotti served as Executive Director of Licensing for Ligand Pharmaceuticals Incorporated, a drug discovery and development company. From 1986 to 1995, Mr. Scotti served in various positions at Reed & Carnrick Pharmaceuticals, a pharmaceutical company, most recently as Vice President of Marketing and Business Development. Mr. Scotti holds a B.S.E. in Biomedical Engineering from the University of Pennsylvania.

William R. Shanahan, Jr., M.D., J.D., has served as our Vice President and Chief Medical Officer since March 2004. From August 2000 to March 2004, Dr. Shanahan served as Chief Medical Officer for Tanox, Inc., a biopharmaceutical company. From October 1994 to August 2000, Dr. Shanahan held

various positions at Isis Pharmaceuticals, Inc., a biopharmaceutical company, most recently as Vice President, Drug Development. From 1989 to 1994, Dr. Shanahan served as Director, Clinical Research for Pfizer Central Research, a pharmaceutical company. From 1986 to 1989, Dr. Shanahan held various positions at Searle Research & Development, a pharmaceutical company subsequently acquired by Pfizer, most recently as Director, Clinical Research. Dr. Shanahan holds an A.B. from Dartmouth College, an M.D. from the University of California, San Francisco and a J.D. from Loyola University, Chicago.

Steven W. Spector, J.D., has served as our Senior Vice President and General Counsel since June 2004. Mr. Spector served as our Vice President and General Counsel from October 2001 to June 2004. Mr. Spector has also served as our Secretary since November 2001. Mr. Spector is a member of the board of directors and the immediate-past President of the Association of Corporate Counsel, San Diego. Prior to joining Arena, Mr. Spector was a partner with the law firm of Morgan, Lewis & Bockius LLP, where he worked from 1991 to October 2001. Mr. Spector was a member of the Morgan Lewis Technology Steering Committee. Mr. Spector was our outside corporate counsel from 1998 to October 2001. Mr. Spector holds a B.A. and a J.D. from the University of Pennsylvania.

Compensation Discussion and Analysis

Introduction

This section provides an overview and analysis of our executive officer compensation program and policies, material compensation decisions we have made under such program and policies, and material factors that we considered in making those decisions. Later in this proxy statement, you will find a series of tables containing specific information about the compensation earned or paid in 2007 to the following individuals, whom we refer to as our Named Executive Officers: Messrs. Lief, Hoffman and Spector and Drs. Behan and Shanahan. The below discussion is intended to help you understand the detailed information provided in those tables and to put that information into context with our overall executive officer compensation program.

Executive Officer Compensation Philosophy, Objectives and Development

We believe that the performance of our executive officers has the potential to significantly impact our ability to achieve our corporate goals. We, therefore, place considerable importance on the design and administration of our executive officer compensation program. This program is intended to enhance stockholder value by attracting, motivating and retaining qualified individuals to perform at the highest of professional levels and to contribute to our growth and success. Accordingly, our executive officer compensation program is designed to provide executive officers with compensation opportunities that are tied to their individual performance, as well as our overall corporate performance. Each executive officer's compensation package is comprised of three key elements: (i) base salary, (ii) performance-based cash incentives and (iii) stock-based compensation. Our executive officers are also entitled to health and welfare benefits, and, as discussed below, certain of them may be entitled to receive additional benefits upon termination of their employment. These additional elements of executive compensation, together with the three key elements, are intended to align the interests of our executive officers with those of our stockholders.

Our compensation packages are also designed to be competitive in our industry. The Compensation Committee consults with compensation consultants, legal counsel and other advisors in designing our compensation program, including in relation to our corporate goals and in evaluating the competitiveness of individual compensation packages. In such evaluation, the Compensation Committee periodically reviews and analyzes executive officer compensation provided by other companies in our industry.

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

Our overall compensation philosophy is to pay our executive officers cash compensation that is at approximately the median level relative to a selected peer group of companies and to provide opportunities, through incentives, to attain above-market total compensation if we satisfy certain key performance goals. The main principles of our compensation strategy include the following:

Compensation decisions are driven by a pay-for-performance philosophy;

Compensation should be tied to both corporate and individual performance; and

Higher than median compensation can be earned through an executive officer's and the company's extraordinary performance.

As part of the process for setting executive compensation, our Chief Executive Officer provides the Compensation Committee with his performance assessments of the company and our executive officers. He also recommends to the Compensation Committee salaries, cash incentive opportunities, cash incentive awards and equity grants for executive officers other than himself. The Compensation Committee can accept, reject or modify such recommendations in its discretion. The Compensation Committee also considers the recommendations of its independent consultant, peer company data, San Diego and national industry compensation surveys, and factors such as the past, current and expected contributions of each executive officer, our corporate performance, the mix of compensation that would be most appropriate for each executive officer and the executive officer's particular responsibilities, experience, level of accountability and decision authority.

While the Compensation Committee meets regularly in executive session, various members of management, including our Chief Executive Officer, Chief Financial Officer and General Counsel, and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, provide financial or other background information or advice or otherwise participate in Compensation Committee meetings. Our General Counsel attends meetings of the Compensation Committee as the Secretary. Our Chief Executive Officer is not present during any deliberations or determinations of the Compensation Committee regarding his compensation.

In determining our executive officers' cash incentive awards for 2007 and developing the 2008 executive compensation program, the Compensation Committee considered what it viewed as our strong corporate performance in 2007, including our success in meeting preset goals, and the importance of keeping our executive officers focused on corporate and individual goals that are set for future achievement.

The Compensation Committee retained Frederic W. Cook & Co., Inc. as its independent compensation consultant to advise it regarding executive compensation and other compensation matters in 2007. For 2007, the compensation consultant (i) helped develop long-term incentives for executive officers and other employees, including our performance-based restricted stock unit awards, (ii) reviewed and made recommendations about our non-employee director compensation program and (iii) reviewed and made recommendations about our equity granting practices and procedures.

The compensation consultant's findings and recommendations were based in part on market data for a "peer" group of biotechnology and biopharmaceutical companies, which changes from time to time based on corporate developments, including clinical and commercial progress, affecting us and other companies in our industry. The Compensation Committee selects the peer group in consultation with its compensation consultant and other members of the Board, including our Chief Executive Officer.

2007 Peer Group. In determining the number and type of equity awards to grant to executive officers in 2007, around the end of 2006, the Compensation Committee updated our peer group taking into account our and the selected companies' development stages, market capitalizations, revenues and earnings. This 2007 peer group consisted of the following companies: Cell Genesys, Inc., Connetics Corporation, Dendreon Corporation, Enzo Biochem, Inc., Exelixis, Inc., Human Genome Sciences, Inc.,

InterMune, Inc., Isis Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Medarex, Inc., The Medicines Company, Noven Pharmaceuticals, Inc., Nuvelo, Inc., Onyx Pharmaceuticals, Inc., Senomyx, Inc., Telik, Inc., and Trimeris, Inc. The Compensation Committee also looked at the 2007 peer group in modifying the compensation of our non-employee directors in 2007.

Elements of Our Compensation Program

1. Base Salary

We generally target base annual salaries to be at approximately the market median of our peer group for executive officers having similar responsibilities, but the salary for any particular executive officer may be higher or lower than the market median depending on such factors as the individual's overall mix of base salary, performance-based cash incentives and stock-based compensation, the individual's historical base salary, the individual's experience and background, the individual's past performance and expected future contribution, the movement of salaries in the marketplace, and our corporate performance during the prior year. The purpose of base salary is to provide fixed compensation to attract and retain an employee with the qualifications desired for the particular position. The Compensation Committee's philosophy in recent years has been to make what it views as modest increases in salary for executive officers, except where an individual's salary was found to be significantly below market when compared to the selected peer group, and to use equity and performance-based cash compensation to motivate and retain our executive officers. The Compensation Committee did not engage its compensation consultant to review annual salaries for executive officers in 2007 as it had in 2006, but rather relied on its consultant's 2006 report, its consultant's view that the Committee could continue to rely on such report, and more recent industry surveys. The consultant's 2006 report was based on a peer group that consisted of the following companies: Antigenics Inc., Arqule, Inc., CancerVax Corporation, Cell Genesys, Inc., Cell Therapeutics, Inc., Connetics Corporation, Curagen Corporation, Dendreon Corporation, Enzo Biochem, Inc., Exelixis, Inc., Guilford Pharmaceuticals, Inc., InterMune, Inc., Isis Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Maxim Pharmaceuticals, Inc., Medarex, Inc., Noven Pharmaceuticals, Inc., Trimeris, Inc., and XOMA Ltd.

2. Performance-based cash incentives

In early 2007, the Compensation Committee approved the 2007 Annual Incentive Plan for our executive officers. Under this cash incentive plan, each participant was assigned an incentive target that was expressed as a percentage of annual base salary, and the participant's incentive award was based on the achievement of preestablished corporate and individual goals. All participants had the same corporate goals, which we believed would align the interests of our executive officers with one another and with our stockholders. The corporate and individual goals were approved by the Compensation Committee after taking into account the views and recommendations of other members of our Board of Directors (including our Chief Executive Officer), which also approved the goals.

The corporate goals for 2007 related to the following categories: (i) progress in internal clinical programs, (ii) progress in partnered programs, (iii) progress in research programs and (iv) finance. Individual goals were tailored for each executive officer based on our business plan and budget for the coming year, the Chief Executive Officer's recommendations for each executive officer other than himself, the executive officer's responsibilities and the Compensation Committee's view about the corporate benefits of achieving each goal. The individual goals for 2007 related to the following categories: (i) progress and milestones in internal and partnered programs, (ii) budget and finance, (iii) compliance and risk mitigation, (iv) corporate governance, (v) corporate planning, (vi) strategic opportunities, (vii) intellectual property and (viii) investor and analyst relations. Corporate and individual goals were intended to reflect a mix of short- and long-term performance objectives.

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

All of our executive officers participated in the 2007 Annual Incentive Plan. The following table lists our Named Executive Officers, their incentive target under the plan expressed as a percentage of their annual base salary, and the relative weighting assigned to corporate and individual goals:

Named Executive Officer	Incentive Target	Relative Weighting	
		Corporate Goals	Individual Goals
Jack Lief	50%	75%	25%
Robert E. Hoffman, C.P.A.	35%	60%	40%
Dominic P. Behan, Ph.D.	35%	60%	40%
William R. Shanahan, Jr., M.D., J.D.	30%	50%	50%
Steven W. Spector, J.D.	35%	60%	40%

The Compensation Committee took into account market data and individual performance and contribution in determining the incentive targets and relative weightings. The weighting of corporate versus individual goals was intended to reflect the participants' responsibilities for their individual areas and the company-wide functions. Mr. Lief's goals were weighted more heavily to the corporate goals than any other of our Named Executive Officers due to his role in overseeing our company-wide functions as our President and Chief Executive Officer, and Dr. Shanahan's goals were weighted more to his individual goals than the other Named Executive Officers due to his significant role in the development of our drug candidates as our Vice President and Chief Medical Officer. Our other Named Executive Officers' goals were weighted more heavily to the corporate goals as their responsibilities involved company-wide functions more than any individual area and to tie their compensation to corporate achievements.

The threshold level of goal achievement under the 2007 Annual Incentive Plan was 50%, below which no incentive award would be paid to an executive officer. This threshold was established to ensure that no awards would be paid if the results achieved were significantly below the target. The Compensation Committee sets goals that it believes will be difficult for our executive officers to fully achieve. Consequently, achieving the target was only expected to occur if both corporate and individual performances were high. Executive officers are eligible to receive incentive awards of up to 125% of the target amount, which allows the Compensation Committee discretion to award more than the target award for extraordinary performance.

The below "Grants of Plan-Based Awards" table shows the incentives that could have been earned under this incentive plan, and the awards earned are included in the below "Summary Compensation Table." All executive officers achieved more than the threshold percentage of goals, but, with the exception of Messrs. Lief and Spector, received less than the target incentive award. The Compensation Committee determined that 80% of the weighted value of the 2007 corporate goals was achieved, and that, with regard to the 2007 individual goals, Messrs. Lief and Spector and Dr. Shanahan achieved 100% of the weighted value, Dr. Behan achieved 90% of the weighted value and Mr. Hoffman achieved 80% of the weighted value. Based only on such achievement, the awards under the plan to our Named Executive Officers would be as follows: Mr. Lief, \$272,000; Mr. Hoffman, \$79,800; Dr. Behan, \$109,074; Dr. Shanahan, \$89,910; and Mr. Spector, \$104,720. The Compensation Committee exercised its discretion to grant awards that were higher than such formulaic amounts based on the quality of achievement of goals and what it viewed as extraordinary efforts and contributions on activities that were important to the company, but not included as goals under the plan.

In early 2008, the Compensation Committee approved corporate and individual goals and a similar annual incentive plan for all of our executive officers for use in determining cash incentive awards for 2008.

3. Stock-based compensation

We believe that equity grants provide our executive officers with the opportunity to share in increases, if any, in the value of our common stock and encourage their ownership in our company. We believe that equity grants reinforce a long-term interest in our corporate performance and directly motivate our executive officers to maximize long-term stockholder value. The equity grants also utilize vesting and, in the case of stock options, exercisability periods that encourage executive officers to continue working for us.

In determining the size and types of equity grants to executive officers, the Compensation Committee considered similar awards to individuals holding comparable jobs in our 2007 Peer Group, our corporate performance against our plan, the individual's performance against his goals, each executive officer's ownership in Arena, the overall share usage under our equity compensation plans for grants to our executive officers, the consequences of granting equity in light of the requirements to expense the value of equity grants and the tax efficiency of various award types.

For 2007, the Compensation Committee granted two forms of equity incentives to executive officers: stock options and performance-based restricted stock units. While both of these incentives are intended to foster the long-term perspective we believe is necessary for continued success, the performance-based restricted stock unit awards are designed to encourage, and compensate our executive officers and other employees for achieving, extraordinary results and to ensure that our executive officers are properly focused on specific drug development and commercialization initiatives that we believe will enhance long-term stockholder value.

In determining the equity grants to executive officers in 2007, the Compensation Committee's overall objective was to grant stock options that were within the broad middle range of the long-term equity grants in our 2007 peer group, but also to take into account the factors specified above for determining equity grants. In 2007, the Compensation Committee granted performance-based restricted stock units to provide greater executive officer equity ownership if we achieve extraordinary drug development and commercialization results embodied by four specific performance goals.

Stock Options

Stock options provide for financial gain derived from stock prices that are higher in the future than the closing market price on the date the options were granted. Under our 2006 Long-Term Incentive Plan, as amended, or LTIP, the exercise price of stock option grants is set at the fair market value of our common stock, which is the closing price of our common stock on the NASDAQ Global Market on the date the options are granted (or if there is no closing price on such date, on the last preceding date on which a closing price was reported). Under the LTIP, we are not permitted to grant stock options at a discount to fair market value. Stock options granted to employees vest 25% per year over four years from the date of grant and are exercisable for up to 10 years from the date of grant. We believe that the vesting restrictions help retain executive officers and that the 10-year exercise period provides incentive for our executive officers to execute on our long-term business plan. We generally make stock option grants to continuing employees, including executive officers, on an annual basis. Our policy is to make such grants three trading days after our announcement of financial results for the prior year. In addition, we generally make an initial stock option grant to all new employees on a preset day in the month following the employee's date of hire.

All grants to executive officers require the approval of the Compensation Committee. The Compensation Committee may delegate to (i) a committee of one or more members of our Board of Directors the authority to take action on behalf of the Compensation Committee under the LTIP, including the right to grant, cancel, suspend or amend awards and (ii) one or more of our executive officers the right to grant awards to non-executive employees, advisors and consultants. The Compensation Committee has delegated to Mr. Lief the ability to grant up to an aggregate of 120,000

stock options to non-executive employees and consultants each quarter. It is the Compensation Committee's policy for Mr. Lief to report to it any such stock option grants at its next regularly scheduled committee meeting.

2007 Performance-Based Restricted Stock Unit Awards

In 2007, the Compensation Committee added performance-based restricted stock unit awards to the mix of compensation for our executive officers. These awards provide executive officers and other employees until February 26, 2012 to achieve four specific drug development and strategic performance goals. A fixed number of awards will be earned for each milestone that is successfully achieved. Once earned, the awards will remain unvested until the performance period is complete. The awards that have been earned at February 26, 2012 will vest and be settled in shares of our common stock, with the holder receiving one share of common stock for each award earned and vested. Termination of employment prior to vesting will result in the forfeiture of any earned (as well as unearned) awards, except for limited circumstances such as termination due to death, disability or a change in control.

The performance goals were established to require significant efforts and results that are expected to drive significant stockholder value, if achieved, thereby further aligning employee and stockholder interests. Each of the performance goals is designed to be a significant milestone for us, the attainment of which is not assured.

Depending on whether we have achieved one, two, three or all four of the performance goals on or before February 26, 2012 and if the particular executive officer is still employed on such date, then the performance stock unit awards would vest as follows: 25% if one goal is achieved, 50% if two goals are achieved, 87.5% if three goals are achieved and 100% if all four goals are achieved.

Below are the number of performance-based restricted stock unit awards our Compensation Committee granted to our Named Executive Officers in February 2007.

Named Executive Officer	Performance-based Restricted Stock Unit Awards(1)
Jack Lief	300,000
Robert E. Hoffman, C.P.A.	100,000
Dominic P. Behan, Ph.D.	100,000
William R. Shanahan, Jr., M.D., J.D.	80,000
Steven W. Spector, J.D.	100,000

(1) Maximum number that may be earned for achieving all four performance goals.

Employee Stock Purchase Plan

We also have adopted the 2001 Employee Stock Purchase Plan, as amended, or ESPP, as a further benefit to executive officers, as well as other employees, and to encourage employee ownership. Under the ESPP, participants may elect to have a portion of their cash compensation withheld for purchases of our common stock on certain dates set forth in the plan. The price of our common stock purchased under the ESPP is equal to 85% of the lower of the fair market value of our common stock on the date of enrollment or the exercise date of the purchase period.

4. Other Benefits and Post-Termination Compensation

All of our executive officers, as well as our other regular, full-time employees, are eligible for a variety of health and welfare and paid time-off benefits. We believe that reliable and competitive health and welfare and paid time-off benefits help ensure that we have a productive and focused workforce.

401(k) Plan and Company Match

Employees are eligible to participate in our 401(k) plan beginning on their hire date. Employees may make pre-tax or after tax (Roth) contributions of up to 50% of gross cash compensation into the plan, up to the annual limit established by the IRS. Subject to limits established by the IRS, we match 100% of each of the participant's voluntary contributions, subject to a maximum match of 6% of the participant's gross cash compensation. This match vests over a five-year period from the individual's date of hire.

Life and Disability Coverage

We provide all regular, full-time employees with a life insurance policy equal to four times the employee's annual salary, up to a maximum coverage of \$500,000. Such employees are also covered by short- and long-term disability plans that coordinate with the California State Disability plan.

Perquisites and Other Benefits

We did not provide any of our Named Executive Officers or other senior members of management with perquisites in 2007 that exceeded \$10,000 in the aggregate for any person, and do not expect to do so in 2008.

Post-Termination Compensation

We have entered into Termination Protection Agreements and have a Severance Benefit Plan that may require us to provide compensation and benefits to certain of our executive officers. The agreements and the plan are summarized below and more detail regarding potential payouts is provided below under "Potential Post-Employment Payments Table."

Termination Protection Agreements. In 2002, we entered into Termination Protection Agreements because we determined that it was appropriate to provide certain of our executive officers severance compensation if there is a change in control and the executive officer's employment is terminated under certain circumstances. We did this to promote the ability of our executive officers to keep focused on corporate interests and to act in the best interests of our stockholders even though their employment could be terminated as a result of the change in control. These agreements were put into place after one of our stockholders acquired approximately 28% of our outstanding common stock. In addition, as part of our normal course of business, we engage in discussions with other companies about possible collaborations and other ways in which we may work together to further our respective long-term objectives and many larger, more established companies consider companies at similar stages of development to ours as potential acquisition targets. In certain scenarios, the potential for merger or being acquired may be in the best interests of our stockholders. Our Termination Protection Agreements reflect our views regarding which executive officers are more likely to be terminated in a change-in-control transaction and which executive officers would likely require more time to get a new job.

Severance Benefit Plan. In 2006, the Compensation Committee approved the Severance Benefit Plan for certain executive officers. Separation benefits are payable if the executive officer's employment is terminated under certain circumstances and are intended to keep our executive officers focused on corporate interests while employed and to ease the consequences to an executive officer of a termination of employment. The advantage to us includes our receipt of a waiver and release of claims, which the separated executive officer must provide to us as a condition to receiving benefits.

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

Any payments payable under the Severance Benefit Plan are reduced by severance benefits payable by us under the Termination Protection Agreements or any other agreement, policy, plan, program or arrangement.

Tax Considerations

We intend that all incentive payments be deductible for tax purposes unless it would undermine our ability to meet our primary compensation objectives. We also take into account the tax effects of various forms of compensation and the potential for excise taxes to be imposed on our executive officers. There are various provisions of the Internal Revenue Code of 1986, as amended, or the Code, which we consider in determining compensation, including the following:

Section 162(m). We consider the potential impact of Section 162(m) of the Code, which denies a Federal income tax deduction for any individual compensation exceeding \$1,000,000 in any taxable year for the chief executive officer and the four highest compensated employees other than the chief executive officer. This limitation does not, however, apply to compensation that is performance-based under a plan that is approved by the stockholders and that meets other requirements. Based on these requirements, we attempt to limit the impact Section 162(m) will have on our ability to deduct compensation, but in appropriate circumstances we will pay compensation that is not deductible under Section 162(m) if necessary and in the best interests of our stockholders.

Sections 280G and 4999. Any payment or benefit provided under our Termination Protection Agreements or our Severance Benefit Plan in connection with a change-in-control transaction may be subject to an excise tax under Section 4999 of the Code. These payments also may not be eligible for a company tax deduction pursuant to Section 280G of the Code. If any of these payments or benefits are subject to the excise tax, they may be reduced to provide the individual with the best after-tax result. Specifically, the individual will receive either a reduced amount so that the excise tax is not triggered, or the individual will receive the full amount of the payments and benefits and then be liable for any excise tax.

Compensation Committee Report

The Compensation Committee, comprised of independent directors, reviewed and discussed the above Compensation Discussion and Analysis with our management. Based on such review and discussions, the Compensation Committee recommended to our Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement and incorporated into our Annual Report on Form 10-K for the fiscal year ended December 31, 2007.

Harry F. Hixson, Jr., Ph.D.
J. Clayburn La Force, Jr., Ph.D.
Christine A. White, M.D.

Summary Compensation Table for Fiscal Years Ended December 31, 2007 and 2006

In 2007, the Compensation Committee approved increases in annual base salary for each of our Named Executive Officers, such that Mr. Lief's annual base salary was increased from \$620,000 to \$640,000; Mr. Hoffman's annual base salary was increased from \$275,000 to \$285,000; Dr. Behan's annual base salary was increased from \$358,800 to \$371,000; Dr. Shanahan's annual base salary was increased from \$321,400 to \$333,000; and Mr. Spector's annual base salary was increased from \$327,600 to \$340,000. The following table summarizes the total compensation of our Named Executive Officers for the fiscal years ended December 31, 2007 and 2006.

Name and Principal Position	Year	Salary \$(1)	Stock Awards \$(2)	Option Awards \$(3)	Non-Equity Incentive Plan Compensation \$(4)	All Other Compensation \$(5)	Total (\$)
Jack Lief President, Chief Executive Officer and Chairman of the Board	2007	\$ 638,889	\$ 219,461	\$ 1,968,705(6)	\$ 325,000	\$ 14,034	\$ 3,166,089
	2006	619,431	399,133	404,907	260,000	13,734	1,697,205
Robert E. Hoffman, C.P.A. Vice President, Finance and Chief Financial Officer	2007	284,444	84,000	218,461	90,000	30,476(7)	707,381
	2006	273,056	77,000	153,170	82,000	24,309(7)	609,535
Dominic P. Behan, Ph.D. Senior Vice President, Chief Scientific Officer and Director	2007	370,323	92,931	300,749	125,000	14,034	903,037
	2006	358,033	184,167	190,804	97,000	13,734	843,738
William R. Shanahan, Jr., M.D., J.D. Vice President and Chief Medical Officer	2007	332,356		229,571	90,000	14,034	665,961
	2006	320,878		149,386	75,000	13,734	558,998
Steven W. Spector, J.D. Senior Vice President, General Counsel and Secretary	2007	339,312	84,000	297,509	125,000	33,649(8)	879,470
	2006	326,900	77,000	179,832	97,000	26,333(8)	707,065

- (1) In accordance with SEC rules, the compensation described in this table does not include medical or other benefits received by our Named Executive Officers that are available generally to all of our regular, full-time employees and certain perquisites and other personal benefits received by our Named Executive Officers which, in the aggregate, did not exceed \$10,000 for any Named Executive Officer. Amounts earned but deferred at the election of our Named Executive Officer pursuant to our 401(k) plan are included in the "salary" column.
- (2) Represents the dollar amount recognized for financial statement reporting purposes for the designated fiscal year in accordance with Statement of Financial Accounting Standards, or SFAS, No. 123R, "Share-Based Payment," which includes amounts from stock awards granted prior to our adoption of SFAS No. 123R in 2006 as well as awards granted in 2006 and 2007.
- (3) Represents the dollar amount recognized for financial statement reporting purposes for the designated fiscal year in accordance with SFAS No. 123R, which includes amounts from option awards granted prior to 2006 and those granted in 2006 and 2007, except that estimates of forfeitures related to vesting under SFAS No. 123R have been excluded. For the relevant assumptions used in determining these amounts, refer to Note 8 to our audited consolidated financial statements included in our annual report on Form 10-K as filed with the SEC on March 5, 2008, Note 8 to our audited consolidated financial statements included in our annual report on Form 10-K as filed with the SEC on March 6, 2007 and Note 1 to our audited consolidated financial statements included in our annual report on Form 10-K as filed with the SEC on March 2, 2005.
- (4) Represents cash awards earned pursuant to our 2006 and 2007 Annual Incentive Plans, as further described below in the "Grants of Plan-Based Awards" table and the above "Compensation

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

Discussion and Analysis." For both years presented, cash awards earned were paid in the subsequent fiscal year.

- (5) Represents matching contributions to our 401(k) plan made on behalf of our Named Executive Officers and life insurance premiums paid by us for our Named Executive Officers.
- (6) In June 2006, we began granting employee stock options that provide for continued vesting after an individual leaves the company if (i) the individual's employment is terminated other than for cause, (ii) such individual is at least 60 years old, and (iii) such individual has provided at least 10 years of service to the company. The stock options included in this table vest over a four-year period, but, as Mr. Lief is over 60 years old and has provided over 10 years of service to the company, in July 2007, we recorded the unrecognized compensation expense for all of the stock options granted to Mr. Lief after June 2006.
- (7) After their annual anniversary hire date, each of our employees may elect to be paid for unused vacation time in the form of additional salary. In addition to items noted in footnote 5 above, this number reflects Mr. Hoffman's election to be paid \$16,442 in the form of additional salary for three weeks of unused vacation time in 2007 and \$10,577 in the form of additional salary for two weeks of unused vacation time in 2006.
- (8) In addition to items noted in footnote 5 above, this number reflects Mr. Spector's election to be paid \$19,615 in the form of additional salary for three weeks of unused vacation time in 2007 and \$12,600 in the form of additional salary for two weeks of unused vacation time in 2006.

In January 2008, the Compensation Committee approved increases in annual base salaries for our Named Executive Officers, such that Mr. Lief's annual base salary was increased to \$670,000; Mr. Hoffman's annual base salary was increased to \$300,000; Dr. Behan's annual base salary was increased to \$389,000; Dr. Shanahan's annual base salary was increased to \$346,000; and Mr. Spector's annual base salary was increased to \$365,000.

Grants of Plan-Based Awards During Fiscal Year Ended December 31, 2007

The following table provides information on estimated future payouts under non-equity incentive plans and stock awards and stock options granted to our Named Executive Officers during the fiscal year ended December 31, 2007.

Name	Grant Date	Approval Date(4)	Estimated Future Payouts Under Non-Equity Incentive Plan Awards(1)			Estimated Future Payouts Under Equity Incentive Plan Awards(2)(3)			All Other Option Awards: Number of Securities Underlying Options (#)(3)	Exercise or Base Price of Option Awards (\$/sh) (5)	Grant Date Fair Value of Stock and Option Awards (\$)(6)
			Threshold (\$)	Target (\$)	Maximum (\$)	Threshold (#)	Target (#)	Maximum (#)			
Jack Lief	2/26/07	1/22/07	160,000	320,000	400,000						
	2/26/07	2/26/07	\$	\$	\$	75,000	300,000	300,000	180,000	\$ 13.50	\$ 1,457,568
Robert E. Hoffman, C.P.A.	2/26/07	1/22/07	49,875	99,750	124,688						
	2/26/07	2/26/07				25,000	100,000	100,000	35,000	13.50	283,416
Dominic P. Behan, Ph.D.	2/26/07	1/22/07	64,925	129,850	162,313						
	2/26/07	2/26/07				25,000	100,000	100,000	60,000	13.50	485,856
William R. Shanahan, Jr., M.D., J.D.	2/26/07	1/22/07	49,950	99,900	124,875						
	2/26/07	2/26/07				20,000	80,000	80,000	45,000	13.50	364,392
Steven W. Spector, J.D.	2/26/07	1/22/07	59,500	119,000	148,750						
	2/26/07	2/26/07				25,000	100,000	100,000	60,000	13.50	485,856

- (1) Our 2007 Annual Incentive Plan was our only non-equity incentive plan in 2007. The amounts shown in the "threshold" column reflect the minimum payment level under our 2007 Annual Incentive Plan, which is 50% of the amount shown in the "target" column. The amounts shown in the "maximum" column are 125% of the respective target amounts. These amounts are based on each Named Executive Officer's 2007 annual salary.
- (2) The performance-based restricted stock unit awards granted on February 26, 2007 provide our Named Executive Officers (and other employees) until February 26, 2012 to achieve four specific drug development and strategic performance goals. A fixed number of awards will be earned for each milestone that is successfully achieved. Once earned, the awards will remain unvested until the performance period is complete. The awards that have been earned at February 26, 2012 will vest and be settled in shares of our common stock, with the holder receiving one share of common stock for each award earned and vested. Termination of employment prior to vesting will result in the forfeiture of any earned (as well as unearned) awards, except for limited circumstances such as termination due to death, disability or a change in control. Depending on whether we have achieved one, two, three or all four of the performance goals on or before February 26, 2012 and if the Named Executive Officer is still employed on such date, then the performance stock awards would vest as follows: 25% if one goal is achieved, 50% if two goals are achieved, 87.5% if three goals are achieved and 100% if all four goals are achieved. The amounts shown in the "threshold" column represent the minimum achievement of one of the four milestones, which is 25% of the total grant. The amounts shown in the "target" and "maximum" columns are 100% of the total grant.
- (3) All awards granted in 2007 were granted under our LTIP.

- (4) We generally make stock option grants to continuing employees, including executive officers, on an annual basis. Our policy is to make such grants three trading days after our announcement of financial results for the prior year. Our Compensation Committee approves such grants in a meeting that precedes the grant date, and, in the case of these stock option grants, such meeting occurred on January 22, 2007. The Compensation Committee approved the performance-based restricted stock unit awards on the same date they were granted.
- (5) In all cases, the exercise price of such option awards was equal to the closing market price of our common stock on the grant date as reported on the NASDAQ Global Market.
- (6) Represents the full value of each award that would be recognized for financial statement reporting purposes over the applicable vesting period in accordance with SFAS No. 123R. For the relevant assumptions used in determining these amounts, refer to Note 8 to our audited consolidated financial statements included in our annual report on Form 10-K as filed with the SEC on March 5, 2008. The amount of these awards that was expensed in 2007 is included above under "Summary Compensation Table."

See "Compensation Discussion and Analysis" above for additional information regarding targets for payment of cash incentives, performance criteria on which cash incentives and the number of stock and option awards were based and for additional information regarding our grant timing, dating and pricing policies.

Individual cash incentive awards under our 2007 Annual Incentive Plan were determined in early 2008 based upon the extent to which goals were achieved, the quality of achievement, the weighting of each goal and what the Compensation Committee viewed as extraordinary efforts and contributions on activities that were important to the company, but not included as goals under the plan.

All stock options granted to our Named Executive Officers are incentive stock options to the extent permissible under the Internal Revenue Code. All such stock options vest 25% per year over four years from the date of grant and are exercisable for up to 10 years from the date of grant. All stock options granted prior to the approval of our LTIP on June 12, 2006 were granted pursuant to stock option plans that allowed them to be exercised prior to vesting, subject to repurchase at the original exercise price in the event of termination. Our LTIP does not allow stock options to be exercised prior to vesting.

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

Outstanding Equity Awards at Fiscal Year Ended December 31, 2007

The following table provides information on all stock options and any unvested stock awards held by our Named Executive Officers on December 31, 2007.

Name	Option Awards				Stock Awards			
	Number of Securities Underlying Unexercised Options (#) Exercisable(1)	Number of Securities Underlying Unexercised Options (#) Unexercisable(1)	Option Exercise Price (\$)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested (\$)(2)	Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)(3)	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested (\$)(2)
Jack Lief	70,000		16.00	1/16/11				
	170,000		\$ 12.25	1/15/12		\$		\$
					24,000	187,920		
	100,000		6.00	1/18/14	(4)			
	124,350		6.16	1/17/15				
	89,000		16.80	1/20/16				
	5,250	15,750	10.52	7/28/16				
	180,000	13.50	2/26/17			75,000	587,250	
Robert E. Hoffman, C.P.A.	5,000		12.25	1/15/12				
	40,000		6.00	1/18/14				
	30,000		6.16	1/17/15				
	40,000		16.80	1/20/16				
		35,000	13.50	2/26/17	10,000	78,300		
				(4)				
						25,000	195,750	
Dominic P. Behan, Ph.D.	87,500		0.60	3/3/10				
	50,000		24.23	8/22/10				
	85,000		12.25	1/15/12				
	33,332		6.00	1/18/14				
	33,116		6.16	1/17/15				
	40,000		16.80	1/20/16				
		7,500	10.52	7/28/16	10,000	78,300		
2,500	60,000	13.50	2/26/17	(4)				
						25,000	195,750	
William R. Shanahan, Jr., M.D., J.D.	60,000		6.30	4/18/14				
	45,000		6.16	1/17/15				
	25,000		16.80	1/20/16				
		45,000	13.50	2/26/17				
						20,000	156,600	
Steven W. Spector, J.D.	35,000		9.05	9/26/11				
	50,000		6.00	1/18/14				
	45,000		6.16	1/17/15				
	40,000		16.80	1/20/16				
		7,500	10.52	7/28/16	10,000	78,300		
	2,500	60,000	13.50	2/26/17	(4)			
						25,000	195,750	

(1)

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

All stock options vest 25% per year over four years from the date of grant and are exercisable for up to 10 years from the date of grant. All stock options granted prior to the approval of our LTIP on June 12, 2006 were granted pursuant to stock option plans that allowed them to be exercised

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

prior to vesting, subject to repurchase at the original exercise price in the event of termination. Our LTIP does not allow stock options to be exercised prior to vesting.

- (2) Computed by multiplying the closing market price of our common stock on December 31, 2007 of \$7.83 by the number of shares or stock unit awards, as appropriate, that have not vested.
- (3) The performance-based restricted stock unit awards granted on February 26, 2007 provide our Named Executive Officers (and other employees) until February 26, 2012 to achieve four specific drug development and strategic performance goals. A fixed number of awards will be earned for each milestone that is successfully achieved. Once earned, the awards will remain unvested until the performance period is complete. The awards that have been earned at February 26, 2012 will vest and be settled in shares of our common stock, with the holder receiving one share of common stock for each award earned and vested. Termination of employment prior to vesting will result in the forfeiture of any earned (as well as unearned) awards, except for limited circumstances such as termination due to death, disability or a change in control. Depending on whether we have achieved one, two, three or all four of the performance goals on or before February 26, 2012 and if the Named Executive Officer is still employed on such date, then the performance stock awards would vest as follows: 25% if one goal is achieved, 50% if two goals are achieved, 87.5% if three goals are achieved and 100% if all four goals are achieved. The amounts included in this column represent the number of shares earned upon achievement of the threshold performance goals, which is the achievement of one of the four milestones, or 25% of the total grant.
- (4) One-half of these restricted shares of common stock vested on January 20, 2008 and the remaining half is scheduled to vest on January 20, 2009. Subject to certain restrictions on transferability and a risk of forfeiture, the Named Executive Officer has all rights of a stockholder as of the date of grant. Unvested shares of restricted common stock are subject to forfeiture in the event of termination of service.

Option Exercises and Stock Vested During Fiscal Year Ended December 31, 2007

The following table provides information on stock option exercises and stock awards vested during the fiscal year ended December 31, 2007.

Name	Option Awards		Stock Awards	
	Number of Shares Acquired on Exercise (#)	Value Realized on Exercise (\$)(1)	Number of Shares Acquired on Vesting (#)	Value Realized on Vesting (\$)(2)
Jack Lief		\$	20,333	\$ 267,786
Robert E. Hoffman, C.P.A.			5,000	65,850
Dominic P. Behan, Ph.D.	58,552	443,058	9,166	120,716
William R. Shanahan, Jr., M.D., J.D.				
Steven W. Spector, J.D.			5,000	65,850

- (1) Computed by multiplying the difference between the closing market prices of our common stock on the exercise dates and the exercise prices of the stock options by the number of options exercised.
- (2) Computed by multiplying the number of shares vested by the closing market price of our common stock on the vesting date.

Nonqualified Deferred Compensation Table for Fiscal Year Ended December 31, 2007

In 2003, we established a deferred compensation plan for our executive officers, whereby they may elect to defer the shares of restricted stock we have awarded them. Shares deferred in the plan become

restricted stock units. This deferral opportunity was established in part to encourage the participants to continue to hold rights to own common stock in the future that may otherwise be sold to satisfy the participant's tax withholding or other financial obligations upon vesting, and for the purpose of rewarding and incentivizing the participants. Participants can choose to receive distributions under the plan as a lump sum distribution or in installments. A participant's election to defer restricted stock under the plan is irrevocable, but the participant may modify their election to provide for a later distribution date, add additional shares under the plan or to provide for a different form of distribution. In addition, the plan allows for hardship withdrawals, early withdrawals with a penalty, and withdrawals by beneficiaries following the death of a participant. Also, unless in connection with a change in control, no distributions are permitted under the plan to a participant in any taxable year to the extent such distribution would result in the participant receiving an amount of compensation that cannot be deducted by us pursuant to the limitations imposed on the deduction of certain compensation payments under Section 162(m) of the Code. At December 31, 2007, 107,919 shares of restricted stock were held in the deferred compensation plan, and the following table provides information about the activity in the deferred compensation plan as of December 31, 2007.

Name	Aggregate Earnings in Last FY \$(1)	Aggregate Withdrawals/ Distributions (\$)	Aggregate Balance at Last FYE \$(2)
Jack Lief			
Robert E. Hoffman, C.P.A.(3)	\$ (95,250)	\$ (87,813)	\$ 146,813
Dominic P. Behan, Ph.D.	(402,179)		619,893
William R. Shanahan, Jr., M.D., J.D.			
Steven W. Spector, J.D.			

- (1) Any earnings in the last fiscal year represent a change in the closing market price of our common stock. Neither the company nor any of the Named Executive Officers made additional contributions to the deferred compensation plan in 2007. Accordingly, the amounts included in this column are not included in the above "Summary Compensation Table."
- (2) Aggregate balance at last fiscal year-end was computed by multiplying the closing market price of our common stock on December 31, 2007 of \$7.83 by the number of shares issuable under the deferred compensation plan. Of the amounts reflected in this column, \$120,563 and \$509,057 were previously reported as compensation in previous years' summary compensation tables for Mr. Hoffman and Dr. Behan, respectively.
- (3) Mr. Hoffman elected to receive a distribution of 6,250 shares from the deferred compensation plan on May 16, 2007 when the closing market price of our common stock was \$14.05 per share.

Potential Post-Employment Payments Table as of Fiscal Year Ended December 31, 2007

Messrs. Lief, Hoffman and Spector and Dr. Behan, who are all of our Named Executive Officers that were employed by us in 2002, are each a party to a Termination Protection Agreement, dated December 20, 2002, which provides for a payment equal to the executive officer's annual compensation, continuation of coverage under our health plans and accelerated vesting of all outstanding unvested stock options and restricted shares if the executive officer is terminated without cause or resigns for good reason (as defined in the agreement) within two years following a change in control or if the executive officer is terminated within one year prior to a change in control in anticipation of the change in control. Within five days of termination (or the change in control if a qualifying termination occurs before the change in control), we are required to pay the executive officer a lump sum equal to (i) the executive officer's base salary in effect on the date of the change in control or the termination date, whichever is higher, and (ii) any bonus paid or payable to the executive officer for the year preceding the change in control or the termination date, whichever is higher.

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

In early 2006, the Compensation Committee approved a Severance Benefit Plan that provides Messrs. Lief, Hoffman and Spector and Drs. Behan and Shanahan severance benefits upon involuntary termination without cause or voluntary termination with good reason (as defined in the agreement). The benefits include cash severance benefits, continuation of coverage under our health plans, acceleration of stock options and awards that would otherwise have vested through the end of the severance period, and continued stock option exercisability. The cash severance benefits are equal to the number of months in the executive officer's severance period multiplied by the executive officer's monthly base salary at the time of termination plus one-twelfth of the greater of (i) the average of the three annual bonuses paid to the executive officer prior to his termination and (ii) the last annual bonus paid to the executive officer prior to termination. The cash severance benefits are required to be paid in a lump sum within 15 days following our receipt of an effective waiver and release of claims and return of company property. The severance period is 18 months for Mr. Lief and 12 months for the other included executive officers.

Any payments payable under the Severance Benefit Plan are reduced by severance benefits payable by us under the Termination Protection Agreements or any other agreement, policy, plan, program or arrangement.

In accordance with SEC rules, the below table provides information on the amounts payable upon termination of our Named Executive Officers assuming the triggering event (which would be their separation) took place on December 31, 2007. Information on certain tax implications of post-termination payments is included above under "Tax Considerations."

Name and Benefit	Termination Protection Agreement <i>(Change in Control Required)</i>	Severance Benefit Plan <i>(No Change in Control Required)</i>	Total Potential Payable Upon Termination(1)
Jack Lief			
Salary	\$ 640,000	\$ 960,000	\$ 960,000
Bonus	325,000	390,000	390,000
Benefit continuation	25,493	19,119	25,493
Accelerated vesting of restricted stock(2)	187,920	187,920	187,920
Accelerated vesting of stock options(3)	129,248	129,248	129,248
Total	1,307,661	1,686,287	1,692,661
Robert E. Hoffman, C.P.A.			
Salary	285,000	285,000	285,000
Bonus	90,000	82,000	90,000
Benefit continuation	35,057	17,528	35,057
Accelerated vesting of restricted stock(2)	78,300	39,150	78,300
Accelerated vesting of stock options(3)	43,348	30,823	43,348
Total	531,705	454,501	531,705
Dominic P. Behan, Ph.D.			
Salary	371,000	371,000	371,000
Bonus	125,000	97,000	125,000
Benefit continuation	35,057	17,528	35,057
Accelerated vesting of restricted stock(2)	78,300	39,150	78,300
Accelerated vesting of stock options(3)	64,623	43,748	64,623
Total	673,980	568,426	673,980

William R. Shanahan, Jr., M.D., J.D.			
Salary		333,000	333,000
Bonus		75,000	75,000
Benefit continuation		17,528	17,528
Accelerated vesting of restricted stock(2)			
Accelerated vesting of stock options(3)		41,738	41,738
Total		467,266	467,266
Steven W. Spector, J.D.			
Salary	340,000	340,000	340,000
Bonus	125,000	97,000	125,000
Benefit continuation	35,057	17,528	35,057
Accelerated vesting of restricted stock(2)	78,300	39,150	78,300
Accelerated vesting of stock options(3)	60,448	41,661	60,448
Total	638,805	535,339	638,805

- (1) The Severance Benefit Plan payments are reduced for all amounts received under the Termination Protection Agreement.
- (2) No accelerated vesting of performance-based restricted stock unit awards is included since none of the performance goals were achieved on December 31, 2007 when the triggering event was assumed to take place.
- (3) Computed by multiplying the difference between the closing market price of our common stock on December 31, 2007 of \$7.83 and the exercise price of each stock option vested as a result of the termination by the number of accelerated stock options.

Director Compensation

The compensation for our non-employee directors is set forth below. Directors who are also employees do not receive additional compensation for serving as a director.

2007 Fiscal Year

For fiscal year 2007, each of our non-employee directors was eligible to earn the following compensation for their participation on our Board of Directors and its committees:

Equity:

New Directors: 18,000 options to purchase shares of our common stock. The options are 10-year options with an exercise price equal to the closing price of our common stock on the grant date as reported by the NASDAQ Global Market, vesting in equal annual installments over two years.

Ongoing Directors: 12,000 options to purchase shares of our common stock. The options are 10-year options with an exercise price equal to the closing price of our common stock on the grant date as reported by the NASDAQ Global Market, vesting in equal monthly installments over one year.

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

New director grants are made in connection with the new director's appointment to the Board and the annual grants are made to ongoing directors three trading days after our announcement of our prior year's financial results. For directors that did not serve for the full fiscal year preceding an annual grant, the grant is pro-rated based on the number of months such director served as a director in the prior year, if any.

Except in the case of a director's death or disability, unvested stock options under the LTIP terminate when the director ceases to be a director. Unless earlier terminated, vested stock options terminate three years after the director ceases to be a director (or, if applicable, an employee) for any reason other than the director's death or disability. In the event of a director's death or disability, the director's stock options become fully vested and exercisable and may be exercised within the earlier of three years after the date of the director's death or disability, as applicable, or the end of the 10-year term of the stock options.

Cash:

Retainer: \$20,000 annually, paid quarterly, subject to continuing service as a director. Prior to the beginning of any calendar year or, in the case of a new director, to the extent permitted, upon joining our Board of Directors, each director can irrevocably elect to take 25%, 50%, 75% or 100% of his or her annual retainer, or, in the case of a new director, his or her pro rata retainer in (i) deferred stock units, or DSUs, on a \$1-for-\$1 basis, (ii) stock options to purchase a number of shares of stock determined by dividing three times the retainer amount elected by the fair market value of our common stock, computed at the time the stock options are granted, or (iii) a combination of cash, DSUs and options. The options are 10-year options with an exercise price equal to the closing price of our common stock on the grant date as reported by the NASDAQ Global Market, vesting in approximately equal monthly installments over one year.

If a director joins the Board of Directors after the first quarter of a calendar year, such directors' retainer for that calendar year is reduced pro rata on a quarterly basis.

Meeting Attendance Fees:

General:

In-Person: \$1,000

Telephonic: \$500

Exceptions:

Audit Chair Meeting Attendance Fee:

In-Person: \$3,000

Telephonic: \$1,500

Other Chair Meeting Attendance Fee:

In-Person: \$2,000

Telephonic: \$1,000

In addition, our Board of Directors and the Compensation Committee may authorize additional fees for significant work in informal meetings or for other service to us in the recipient's capacity as a director or committee member. Each non-employee director is also entitled to

reimbursement for all of such director's reasonable out-of-pocket expenses incurred in connection with performing Board business.

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

Director Compensation Table for Fiscal Year Ended December 31, 2007

As described more fully above, the following table summarizes the annual compensation for our non-employee directors during the fiscal year ended December 31, 2007.

Name	Fees Earned or Paid in Cash \$(1)	Option Awards \$(2)	Total (\$)
Donald D. Belcher(3)	\$ 57,500	\$ 157,029	\$ 214,529
Scott H. Bice(4)	47,500	124,645	172,145
Harry F. Hixson, Jr., Ph.D.(5)	44,000	157,029	201,029
J. Clayburn La Force, Jr., Ph.D.(6)	45,000	157,029	202,029
Tina Nova Bennett, Ph.D.(7)	40,000	121,263	161,263
Phillip M. Schneider(8)	6,000		6,000
Christine A. White, M.D.(9)	43,000	179,294	222,294
Randall E. Woods(10)	6,000		6,000

- (1) For each director, includes all meeting attendance fees and the cash retainer earned or paid for the fiscal year ended December 31, 2007, whether or not the director elected to receive his or her cash retainer in cash, stock options or a combination of both.
- (2) Represents the dollar amount recognized for financial statement reporting purposes for the fiscal year ended December 31, 2007 in accordance with SFAS No. 123R, "Share-Based Payment," which includes amounts from options granted in and prior to 2007, except that estimates of forfeitures related to vesting under SFAS No. 123R have been excluded. For the relevant assumptions used in determining these amounts, refer to Note 8 to our audited consolidated financial statements included in our annual report on Form 10-K as filed with the SEC on March 5, 2008 and Note 8 to our audited consolidated financial statements included in our annual report on Form 10-K as filed with the SEC on March 6, 2007.
- (3) Mr. Belcher elected to receive 100% of his annual cash retainer for the fiscal year ended December 31, 2007 in stock options determined by dividing three times the annual retainer amount of \$20,000 by the fair market value of our common stock, computed at the time the stock options were granted. The grant-date fair value of the 4,444 options granted to Mr. Belcher in 2007 in lieu of cash was \$35,986, computed in accordance with SFAS No. 123R. Only the vested portion of the incremental value of these stock options is included in the option awards column. The grant-date fair value of the additional 12,000 options granted to Mr. Belcher in 2007 was \$97,171. Mr. Belcher had a total of 91,476 options outstanding at December 31, 2007. \$9,500 of the meeting fees earned in 2006 and included above were paid to Mr. Belcher in 2007, and \$12,000 of the meeting fees earned in 2007 and included above were paid to Mr. Belcher in 2008.
- (4) Mr. Bice elected to receive 25% of his annual cash retainer for the fiscal year ended December 31, 2007 in stock options determined by dividing three times the \$5,000 portion of his annual retainer amount by the fair market value of our common stock, computed at the time the stock options were granted. The grant-date fair value of the 1,111 options granted to Mr. Bice in 2007 in lieu of cash was \$8,996, computed in accordance with SFAS No. 123R. Only the vested portion of the incremental value of these stock options is included in the option awards column. The grant-date fair value of the additional 12,000 options granted to Mr. Bice in 2007 was \$97,171. Mr. Bice had a total of 58,111 options outstanding at December 31, 2007. \$6,000 of the meeting fees earned in 2006 and included above were paid to Mr. Bice in 2007, and \$11,000 of the meeting fees earned in 2007 and included above were paid to Mr. Bice in 2008.

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

- (5) Dr. Hixson elected to receive 100% of his annual cash retainer for the fiscal year ended December 31, 2007 in stock options determined by dividing three times the annual retainer amount of \$20,000 by the fair market value of our common stock, computed at the time the stock options were granted. The grant-date fair value of the 4,444 options granted to Dr. Hixson in 2007 in lieu of cash was \$35,986, computed in accordance with SFAS No. 123R. Only the vested portion of the incremental value of these stock options is included in the option awards column. The grant-date fair value of the additional 12,000 options granted to Dr. Hixson in 2007 was \$97,171. Dr. Hixson had a total of 91,486 options outstanding at December 31, 2007. \$6,500 of the meeting fees earned in 2006 and included above were paid to Dr. Hixson in 2007, and \$10,000 of the meeting fees earned in 2007 and included above were paid to Dr. Hixson in 2008.
- (6) Dr. La Force elected to receive 100% of his annual cash retainer for the fiscal year ended December 31, 2007 in stock options determined by dividing three times the annual retainer amount of \$20,000 by the fair market value of our common stock, computed at the time the stock options were granted. The grant-date fair value of the 4,444 options granted to Dr. La Force in 2007 in lieu of cash was \$35,986, computed in accordance with SFAS No. 123R. Only the vested portion of the incremental value of these stock options is included in the option awards column. The grant-date fair value of the additional 12,000 options granted to Dr. La Force in 2007 was \$97,171. Dr. La Force had a total of 149,072 options outstanding at December 31, 2007. \$4,500 of the meeting fees earned in 2006 and included above were paid to Dr. La Force in 2007, and \$12,500 of the meeting fees earned in 2007 and included above were paid to Dr. La Force in 2008.
- (7) The grant-date fair value of the 12,000 options granted to Dr. Nova Bennett in 2007 was \$97,171. Dr. Nova Bennett had a total of 57,000 options outstanding at December 31, 2007. \$5,000 of the meeting fees earned in 2006 and included above were paid to Dr. Nova Bennett in 2007, and \$7,000 of the meeting fees earned in 2007 and included above were paid to Dr. Nova Bennett in 2008.
- (8) Mr. Schneider was elected to our Board of Directors on December 11, 2007, and did not receive his initial grant of stock options until January 15, 2008. Mr. Schneider had no stock options outstanding at December 31, 2007. \$1,000 of meeting fees and his cash retainer of \$5,000 earned in 2007 and included above were paid to Mr. Schneider in 2008.
- (9) Dr. White elected to receive 100% of her annual cash retainer for the fiscal year ended December 31, 2007 in stock options determined by dividing three times the annual retainer amount of \$20,000 by the fair market value of our common stock, computed at the time the stock options were granted. The grant-date fair value of the 4,444 options granted to Dr. White in 2007 in lieu of cash was \$35,986, computed in accordance with SFAS No. 123R. Only the vested portion of the incremental value of these stock options is included in the option awards column. The grant-date fair value of the additional 12,000 options granted to Dr. White in 2007 was \$97,171. Dr. White had a total of 41,444 options outstanding at December 31, 2007. \$6,000 of the meeting fees earned in 2006 and included above were paid to Dr. White in 2007, and \$9,500 of the meeting fees earned in 2007 and included above were paid to Dr. White in 2008.
- (10) Mr. Woods was elected to our Board of Directors on December 11, 2007, and did not receive his initial grant of stock options until January 15, 2008. Mr. Woods had no stock options outstanding at December 31, 2007. \$1,000 of meeting fees and his cash retainer of \$5,000 earned in 2007 and included above were paid to Mr. Woods in 2008.

All stock options granted to non-employee directors in the fiscal year ended December 31, 2007 are 10-year options with an exercise price equal to the closing price of our common stock on the date of grant, vesting in approximately equal monthly installments over one year.

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

See "Compensation Discussion and Analysis" above for additional information regarding our grant timing, dating and pricing policies and the discussion above under "2007 Fiscal Year" regarding the 2007 compensation for our non-employee directors.

2008 Fiscal Year

We expect our 2008 compensation for non-employee directors will be substantially similar to the compensation granted during 2007.

Audit Committee

Audit Committee Report

This report of our Audit Committee is not deemed to be "soliciting material," or to be "filed" with the SEC or subject to the SEC's proxy rules (other than as provided in Item 407 of Regulation S-K) or to the liabilities of Section 18 of the Exchange Act, and, irrespective of any general incorporation language, this report shall not be deemed incorporated by reference into any prior or subsequent filing by us under the Securities Act of 1933 or the Exchange Act, except to the extent that we specifically incorporate it by reference into any such filing.

Our management has the primary responsibility for our financial reporting process, accounting principles and internal controls as well as the preparation of our financial statements. The Audit Committee oversees our financial reporting process on behalf of our Board of Directors.

In fulfilling its responsibilities, the Audit Committee appointed Ernst & Young LLP, an independent registered public accounting firm, as our independent auditors for the 2007 fiscal year. The Audit Committee reviewed and discussed with the independent auditors the overall scope and specific plans for their audit. The Audit Committee also reviewed and discussed with the independent auditors and with management our audited consolidated financial statements and the adequacy of our internal control over financial reporting. The Audit Committee met with the independent auditors, without management present, to discuss the results of the independent auditors' audit, the independent auditors' evaluations of our internal control over financial reporting, and the overall quality of our financial reporting. The meetings were also designed to facilitate any desired private communication between the Audit Committee and the independent auditors.

The Audit Committee monitored the independence and performance of the independent auditors. The Audit Committee discussed with the independent auditors the matters required to be discussed by the Statement on Auditing Standards No. 61, as amended (Communication with Audit Committees), as adopted by the Public Company Accounting Oversight Board, or PCAOB, in Rule 3200T. The Audit Committee received the written disclosures and the letter from the independent auditors required by Independence Standards Board Standard No. 1 (Independence Discussions with Audit Committees), as adopted by the PCAOB in Rule 3600T and discussed with the independent auditors the independent auditors' independence. The Audit Committee concluded that the provision of non-audit professional services was compatible with maintaining the independent auditors' independence.

Based on the review and discussions referred to above, the Audit Committee recommended to our Board of Directors that the audited consolidated financial statements be included in our annual report on Form 10-K for the fiscal year ended December 31, 2007, as filed with the SEC. The Audit Committee has also appointed Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2008.

The foregoing report is provided by the following directors, who constitute the Audit Committee:

Donald D. Belcher
Scott H. Bice
Tina Nova Bennett, Ph.D.
Phillip M. Schneider

Independent Auditors' Fees

The following presents aggregate fees billed to us for the fiscal years ended December 31, 2007 and 2006 by Ernst & Young LLP, our independent auditors and principal outside accountants.

Audit Fees. Audit fees were \$514,000 and \$495,929 for the years ended December 31, 2007 and 2006, respectively.

Audit-Related Fees. Audit-related fees were \$25,758 and \$22,033 for the years ended December 31, 2007 and 2006, respectively. The fees in 2007 were primarily related to consultations regarding performance-based restricted stock unit awards, Financial Accounting Standards Board Interpretation No. 48, or FIN 48, and the sale and leaseback of certain of our real property. The fees in 2006 were primarily related to the implementation of Statement of Financial Accounting Standards, or SFAS, No. 123R, "Share-Based Payment."

Tax Fees. Tax fees were \$58,727 and \$0 for the years ended December 31, 2007 and 2006, respectively. The fees in 2007 were related to consultations relating to Internal Revenue Code Section 382, FIN 48 and international tax matters, including our Swiss subsidiary's (Arena Pharmaceuticals GmbH) acquisition of certain drug product facility assets.

All Other Fees. There were no fees billed in either of the years ended December 31, 2007 or 2006 for products or services provided by our independent auditors other than those disclosed above in this section.

Pre-approval Policies and Procedures

The Audit Committee has adopted a policy and procedures for pre-approving all audit and non-audit services to be performed by our independent auditors. The policy requires pre-approval of all services rendered by our independent auditors either as part of the Audit Committee's approval of the scope of the engagement of the independent auditors or on a case-by-case basis. The Audit Committee has authorized its Chair to pre-approve individual expenditures of audit and non-audit services. Any pre-approval decision must be reported to the Audit Committee at the next regularly scheduled Audit Committee meeting. The Audit Committee approved all audit, audit-related and tax fees for 2007 and 2006.

Ratification of Independent Auditors (*Proposal 2*)

The Audit Committee has appointed Ernst & Young LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2008. Ernst & Young LLP has audited our financial statements since our inception in 1997. Our Board of Directors is submitting the appointment of Ernst & Young LLP to the stockholders for ratification as a matter of good corporate practice.

In connection with the audit of the 2007 financial statements, we entered into an engagement letter with Ernst & Young LLP that sets forth the terms by which Ernst & Young LLP will perform audit services for us. The agreement is subject to alternative dispute resolution procedures and an exclusion of punitive damages.

Stockholders are requested in this Proposal 2 to ratify the appointment of Ernst & Young LLP. The affirmative vote of the holders of a majority of the shares of common stock (determined as if our Preferred Stock was converted into common stock) present at the meeting in person or by proxy and entitled to vote will be required to ratify the appointment of Ernst & Young LLP. Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes. Broker non-votes are counted towards a quorum, but are not counted for any purpose in determining whether this matter has been approved.

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

In the event that the stockholders fail to ratify the appointment, the Audit Committee will reconsider its selection of our independent auditors, but may decide not to change its selection. Even if the appointment is ratified, the Audit Committee may appoint different independent auditors at any time if it determines that such a change would be in the stockholders' best interest.

Representatives of Ernst & Young LLP are expected to be present at our 2008 Annual Meeting. They will have the opportunity to make a statement if they desire to do so, and will be available to respond to appropriate questions.

THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE "FOR" THE RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP TO SERVE AS OUR INDEPENDENT AUDITORS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2008.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act requires our directors, executive officers and our 10% or greater stockholders to file reports of ownership of our equity securities and changes in such ownership with the SEC and NASDAQ and to furnish us with copies of such reports.

To our knowledge, based on a review of the copies of such reports furnished to us and written representations that no other reports were required, all Section 16(a) filing requirements applicable to our directors, executive officers and our 10% or greater stockholders were complied with during the fiscal year ended December 31, 2007, except as discussed below.

Dr. Behan filed a Form 5 in 2007 to report a sale he completed in April 2001 pursuant to a Rule 10b5-1 trading plan he had adopted. The sale had not been previously reported.

Stockholder Proposals for the 2009 Annual Meeting

To be considered for inclusion in our proxy statement for next year's annual meeting, stockholder proposals must be in writing, addressed to our Corporate Secretary, and be received at our executive offices at 6166 Nancy Ridge Drive, San Diego, California 92121, no later than the close of business on December 26, 2008. In addition, notice of any stockholder proposal to be presented at next year's annual meeting of stockholders must be received at our executive offices no later than the close of business on February 13, 2009, and no earlier than January 24, 2009. The above dates in this section may change under circumstances set forth in our Bylaws. Stockholders may request a copy of the bylaw provisions relating to stockholder proposals from our Corporate Secretary at the same address.

Notices of intention to present proposals at the 2009 annual meeting of stockholders should be addressed to our Corporate Secretary, Arena Pharmaceuticals, Inc., 6166 Nancy Ridge Drive, San Diego, California 92121. We reserve the right to reject, rule out of order, or take appropriate action with respect to any proposal that does not comply with these and any other applicable requirements.

Annual Report

A copy of our Annual Report for the 2007 fiscal year has been mailed concurrently with this proxy statement to all stockholders entitled to notice of and vote at our 2008 Annual Meeting. The Annual Report is not incorporated into this proxy statement and is not considered proxy solicitation material.

Annual Report on Form 10-K

WE WILL MAIL WITHOUT CHARGE, UPON WRITTEN REQUEST, A COPY OF OUR ANNUAL REPORT ON FORM 10-K, INCLUDING THE FINANCIAL STATEMENTS, SCHEDULES AND LIST OF EXHIBITS. WE WILL FURNISH A COPY OF ANY EXHIBIT TO

SUCH REPORT UPON WRITTEN REQUEST AND PAYMENT OF OUR REASONABLE EXPENSES IN FURNISHING SUCH EXHIBIT. REQUESTS SHOULD BE SENT TO INVESTOR RELATIONS, ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO, CALIFORNIA 92121. OUR SEC FILINGS ARE ALSO AVAILABLE ON OUR WEBSITE AT WWW.ARENAPHARM.COM.

Householding of Proxy Materials

The SEC has adopted rules that permit companies and intermediaries (such as brokers) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This process, which is commonly referred to as "householding," potentially results in a reduced usage of natural resources and cost savings for companies.

A number of brokers with account holders who are our stockholders will be "householding" our proxy materials. A single proxy statement and one annual report will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be "householding" communications to your address, "householding" will continue until you are notified otherwise or until you revoke your consent. Any stockholder at a shared address to which a single copy of the documents was delivered and who wishes to receive a separate copy of the documents can request a copy of the documents by sending a written request to Corporate Secretary, Arena Pharmaceuticals, Inc., 6166 Nancy Ridge Drive, San Diego, California 92121, or contact our Corporate Secretary at 858.453.7200. Also, if, at any time, you no longer wish to participate in "householding" and would prefer to receive a separate proxy statement and annual report in the future, please notify your broker or direct your written request to Corporate Secretary, Arena Pharmaceuticals, Inc., 6166 Nancy Ridge Drive, San Diego, California 92121, or contact our Corporate Secretary at 858.453.7200. Stockholders who currently receive multiple copies of the proxy statement at their address and would like to request "householding" of their communications should contact their broker.

Other Matters

Our Board of Directors knows of no other business that will be presented for consideration at our 2008 Annual Meeting. If other matters are properly brought before our 2008 Annual Meeting, however, it is the intention of the persons named in the accompanying proxy to vote the shares represented thereby on such matters in accordance with their best judgment.

Dated: April 24, 2008

By Order of our Board of Directors

Steven W. Spector
Senior Vice President, General Counsel and Secretary

41

IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.

Proxy Arena Pharmaceuticals, Inc.

**THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS FOR
THE 2008 ANNUAL MEETING OF STOCKHOLDERS
6150 Nancy Ridge Drive, San Diego, California 92121**

The undersigned stockholder of ARENA PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), hereby acknowledges receipt of the Notice of Annual Meeting of Stockholders and Proxy Statement, each dated April 24, 2008, and the Annual Report to Stockholders, and hereby appoints Jack Lief and Steven W. Spector, the President and the Secretary, respectively, of the Company, or each of them, as proxies and attorneys-in-fact, with all powers of substitution, to represent and vote, as set forth on the reverse side, the shares of Common Stock and Preferred Stock of the Company held of record by the undersigned at the close of business on April 14, 2008, at the 2008 Annual Meeting of Stockholders of the Company, which is being held at the offices of the Company at 6150 Nancy Ridge Drive, San Diego, California 92121, on Wednesday, June 11, 2008, at 9:00 a.m. Pacific Time, and at any adjournments or postponements of such meeting, with all powers which the undersigned would possess if personally present at such meeting or at any such postponement or adjournment, and, in their discretion, to vote such shares upon any other business that may properly come before the meeting or any adjournments or postponements thereof.

UNLESS OTHERWISE SPECIFIED BY THE UNDERSIGNED, THE PROXY WILL BE VOTED "FOR" PROPOSALS 1 AND 2 AND WILL BE VOTED BY THE PROXYHOLDERS AT THEIR DISCRETION UPON ANY OTHER BUSINESS THAT MAY PROPERLY COME BEFORE THE ANNUAL MEETING OR ANY ADJOURNMENT OR POSTPONEMENTS THEREOF.

(Items to be voted appear on reverse side.)

Arena Pharmaceuticals, Inc.

Electronic Voting Instructions

You can vote by Internet or telephone!
Available 24 hours a day, 7 days a week!

Instead of mailing your proxy, you may choose one of the two voting methods outlined below to vote your proxy.

VALIDATION DETAILS ARE LOCATED BELOW IN THE TITLE BAR.

Proxies submitted by the Internet or telephone must be received by 11:00 p.m. Pacific Time on June 10, 2008.

Vote by Internet

Log on to the Internet and go to
www.investorvote.com/ARNA
 Follow the steps outlined on the secured website.

Vote by telephone

Call toll free 1-800-652-VOTE (8683) within the United States, Canada & Puerto Rico any time on a touch tone telephone. There is **NO CHARGE** to you for the call.
 Follow the instructions provided by the recorded message.

Using a **black ink** pen, mark your votes with an **X** as shown in this example. Please do not write outside the designated areas.



Annual Meeting Proxy Card Common and Preferred Stock

IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.

A Proposals The Board of Directors recommends a vote FOR all the nominees listed and FOR Proposal 2.

1. Election of Directors:	For	Withhold		For	Withhold		For	Withhold
01 Jack Lief	<input type="radio"/>	<input type="radio"/>	02 Dominic P. Behan, Ph.D.	<input type="radio"/>	<input type="radio"/>	03 Donald D. Belcher	<input type="radio"/>	<input type="radio"/>
04 Scott H. Bice	<input type="radio"/>	<input type="radio"/>	05 Harry F. Hixson, Jr., Ph.D.	<input type="radio"/>	<input type="radio"/>	06 J. Clayburn La Force, Jr., Ph.D.	<input type="radio"/>	<input type="radio"/>
07 Tina Nova Bennett, Ph.D.	<input type="radio"/>	<input type="radio"/>	08 Phillip M. Schneider	<input type="radio"/>	<input type="radio"/>	09 Christine A. White, M.D.	<input type="radio"/>	<input type="radio"/>
10 Randall E. Woods	<input type="radio"/>	<input type="radio"/>						
			For	Against	Abstain			
2. Ratification of appointment of Ernst & Young LLP as independent auditors.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>			

B Non-Voting Items

Change of Address Please print new address below.

Meeting Attendance
 Mark box to the right if you plan to attend the Annual Meeting.

C Authorized Signatures This section must be completed for your vote to be counted. Date and Sign Below

NOTE: Please sign your name(s) EXACTLY as your name(s) appear(s) on this proxy. All joint holders must sign. When signing as attorney, trustee, executor, administrator, guardian or corporate officer, please provide your FULL title.

Edgar Filing: ARENA PHARMACEUTICALS INC - Form DEF 14A

Date (mm/dd/yyyy) Please print date below.

Signature 1 Please keep signature within the box.

Signature 2 Please keep signature within the box.

/ /

QuickLinks

TABLE OF CONTENTS

Information Concerning Solicitation and Voting

Election of Directors (Proposal 1)

Compensation and Other Information Concerning Executive Officers, Directors and Certain Stockholders

Summary Compensation Table for Fiscal Years Ended December 31, 2007 and 2006

Grants of Plan-Based Awards During Fiscal Year Ended December 31, 2007

Audit Committee

Ratification of Independent Auditors (Proposal 2)

Section 16(a) Beneficial Ownership Reporting Compliance

Stockholder Proposals for the 2009 Annual Meeting

Annual Report

Annual Report on Form 10-K

Householding of Proxy Materials

Other Matters